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ABSTRACT
Delivery of therapeutic molecules to the eye has been a complicated task owing to its anatomical
and physiological barriers. This dissertation delineates several formulation strategies to
circumvent dynamic and static constraints hampering the ocular drug delivery.
Advanced vesicular systems, bilosomes and transfersomes, were prepared to improve the
ocular pharmacotherapy of natamycin (NT). NT bilosomes and transfersomes were further loaded
into in situ gel systems which transformed immediately to hydrogel, in the simulated tear fluid,
with good viscoelastic and mucoadhesive properties. In vitro corneal transport studies confirmed
the superior permeability characteristics of NT from the optimized bilosome and transfersome in
situ gel formulations, over control marketed (5 % w/v NT) suspension. In the ocular distribution
studies, considerably higher mean dose normalized drug levels in the ocular tissues from bilosome
and transfersome in situ gel formulations for 6h, compared to that from the control suspension,
demonstrated the effectiveness of ion-sensitive in situ hydrogels of bilosomes and transfersomes
as potential carrier systems for improved and prolonged topical ocular drug delivery.
The magnitude of P-glycoprotein (P-gp) and multidrug resistance protein (MRP1) were
investigated by comparative ocular distribution studies in the P-gp and MRP1 gene knock out (KO)
and wild type (WT) rats. The blood ocular penetration of paclitaxel (PTX), a P-gp substrate and,
methotrexate (MTX), an MRP 1 substrate, were significantly higher in the KO rats compared to
WT rats. These results suggested that the penetration of anticancer substrate drugs across the BOB
is restricted by efflux transporter proteins. Further, the concurrent intravenous administration of
specific P-gp and MRP 1 inhibitors, along with PTX or MTX, in the WT rats resulted in improved
iii

blood ocular penetration of substrate anticancer drugs by effective inhibition of efflux protein
activity in the BOB. The electroretinography (ERG) studies demonstrated that the inhibitor and
substrate interactions did not induce any toxic effects on retina functions. However, at higher
concentration of PTX and MTX showed toxic effects on the retina functions.
Feasibility of coadministration of topical ocular inserts of P-gp inhibitors and
intravenous anticancer substrate drug, PTX, was investigated in rats to examine the potential of
this strategy to improve blood ocular penetration of PTX. Ocular films of P-gp inhibitors were
fabricated by melt cast method and the transocular membrane permeability of the P-gp inhibitors,
elacridar (EQ) and tariquidar (TQ), was investigated in the isolated rabbit cornea. Both EQ and
TQ showed transcorneal permeability but no penetration through Sclera-choroidal retinal
pigmented epithelium (RPE) tissue. The ocular distribution studies in rats showed improved blood
ocular penetration of PTX in the rats co-administered with EQ and TQ. These results demonstrated
that the topically administered P-gp inhibitor effectively inhibits the P-gp activity and thereby
improves ocular chemotherapy. ERG and Ultrastructure analyses of RPE confirmed that the PTXEQ/TQ interactions were compatible with retina.
TA protransfersome gel formulations were successfully prepared with at least two-fold higher drug
load, compared to the marketed topical dosage form, which allows higher, localized, concentration
gradients. Microscopic studies confirmed complete drug dissolution in the lipid phase and rapid
formation of transfersomes on hydration. Significantly higher trans-eyelid TA permeation with the
protransfersome gel formulation – demonstrated their potential in enhancing drug delivery to the
ocular surface and deeper tissues via the eyelid. Experiments in dead rabbits confirmed that TA
iv

efficiently penetrated into the eyelid and formed a depot leading to increasing concentration-time
profiles in all ocular tissues tested. The overall results suggest that trans-eyelid protransferosome
gel formulations can provide a platform for the sustained delivery of therapeutic agents to both the
surface of the eye as well as the anterior and posterior segment ocular tissues.
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CHAPTER 1
INTRODUCTION
1.1. Introduction
Eye, the most important and sensitive organ, regulates the visual sensory activities in
the humans. The architecture of the eye is extremely complex with the intraocular tissues aligned
in two segments, namely, the anterior segment and the posterior segment (Fig 1.1). Conjunctiva,
cornea, aqueous humor (AH), iris, ciliary body, trabecular meshwork, schlemm’s canal, pupil, and
lens are situated in the anterior segment. Most of these tissues control the aqueous humor dynamics
which maintains the intraocular pressure. Sclera, choroid, retina, vitreous humor (VH) and optic
nerve constitutes posterior segment. The rods and cones in the retina play a critical role in

Figure 1.1: Anatomy of the human eye
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processing the visual information in the central nervous system. Any damage, either by
disease or injury, to the eye may lead to the temporary or permanent vision problems
1.1.1. Ocular Protective Barriers
The anatomical and physiological barriers that safeguard the eyes from toxins or xenobiotics from
external environment or systemic circulation are presented in table 1.1.
Table 1.1: Physiological and anatomical protective barriers in the eye.

Physiological

Anatomical

1. Lacrimal discharge

6.

Conjunctiva ultrastructure

2. Tear turnover

7.

Cornea ultrastructure

3. Tear film

8.

Sclera

4. Reflux blinking

9.

Choroid

5. Naso-lacrimal drainage

10.

Bruch’s membrane

6. Pre-corneal metabolism

11.

Blood ocular barriers (BOB)

7. Aqueous humor outflow

o Blood aqueous barriers
o Blood retinal barriers

1.1.1.1.

Physiological barriers

The physiological barriers lower precorneal residence time of the toxins or xenobiotics, from the
external environment (topical), through increased lacrimation, dilution by tear, reflux blinking and
nasolacrimal drainage. Moreover, the precorneal metabolism results in precorneal loss and, thus,
prevents the entry of toxic materials into the ocular compartments (1, 2).
1.1.1.2.

Anatomical Barriers

Anatomical barriers restrict the penetration of toxins from the external environment and protect
the deeper ocular tissues. The conjunctiva vasculature, unique structural features of the cornea,
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with the hydrophilic stroma sandwiched between the hydrophobic epithelium and the endothelium,
and sclera limits the permeability of the xenobiotics (2). The presence of complex blood ocular
barriers (BOB) comprising; blood-aqueous barrier (BAB), and the blood-retinal barrier (BRB),
with tight-junction proteins and the efflux proteins (P-gp/MRP 1), protect the anterior and posterior
segment ocular tissues by preventing the paracellular and/or transcellular transportation of
endobiotics and xenobiotics from the systemic circulation (3, 4).
1.1.2. Eye Ailments
In 2011, as per the World Health Organization (WHO) report, approximately 285 million global
population is suffering from eye ailments. Additionally, National Eye Institute (NEI) reported
more than 30 million individuals in the United States suffering from ocular diseases (5, 6). Agerelated macular degeneration (AMD), diabetic retinopathy (DR), uveitis, retinoblastoma, dry eyes,
conjunctivitis, keratomycosis, blepharitis, postoperative endophthalmitis, corneal ulcers, bacterial
keratitis, mycotic keratitis, choroidal neovascularization (CNV) and retinitis pigmentosa were the
most commonly encountered eye diseases worldwide (7-10). These diseases involve infection,
inflammation and/or oxidative stress (alone or in combination) of anterior and posterior segment
ocular tissues. It is predicted that these numbers would be doubled by 2050 (2,11,12). Alone in
USA, approximately $40 billion/year expenditure is incurred in the treatment of ocular disorders,
and, more than a half of the treatment regimen includes anti-infective and steroidal antiinflammatory agents (11,12).
Currently, conventional, topical ophthalmic formulations are utilized for the treatment of
external eye surface and anterior ocular tissue infections/inflammation (1,2). A host of
physiological and anatomical protective barriers shorten the precorneal residence and restricts the
ocular penetration of therapeutic agents from these topical formulations (1,2,13). Thus, frequent
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administration (3 - 6 times/day) is often needed to maintain therapeutic drug levels (1,2,13), which
leads to noncompliance issues. Moreover, the topical route of administration has not been effective
in the treatment of conditions affecting the back-of-the eye, for which intravitreal
injections/systemic administration are the best options (13,14). Poor patient compliance and
injection associated risks, however, are major challenges for intravitreal injections (13,15). While,
drugs from systemic circulation need to overcome the blood ocular barriers for which higher dose
administration is required, that could result in systemic toxicity (14). Hence, there is an urgent
need for robust noninvasive drug delivery platforms that can improve and prolong therapeutic drug
levels in the anterior and posterior ocular segments.
1.2. Specific Objectives:
The major objective of this project is to develop novel topical ophthalmic formulations
of Natamycin (NT), an anti-fungal agent, Triamcinalone acetonide (TA), a steroidal antiinflammatory agent, and P-gp/Mrp 1 inhibitors. NT and TA are used in the treatment of ocular
fungal infections and inflammations. P-gp/Mrp 1 inhibitors are utilized in the inhibition of the Pgp/Mrp1 activity in the BOB to improve blood ocular penetration of chemotherapeutics. The
selected molecules were formulated and tested for in vitro and in vivo performance to demonstrate
the potential of advanced vesicular in situ hydrogels and melt-cast films for improved and
prolonged ocular pharmacotherapy.
1.3. Specific Aims
1. Development and evaluation of the ion sensitive in situ hydrogels of NT loaded vesicular
systems for improved and prolonged ocular delivery.
2. Screening, development and evaluation of P-gp/Mrp1 inhibitor loaded topical melt cast films
for improved blood ocular penetration of substrate chemotherapeutic drugs.
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2.1. Evaluation of the impact of efflux proteins activity and inhibition in the blood ocular
barriers for improved ocular delivery of chemotherapeutic agents.
2.2. Development and evaluation of specific inhibitor loaded topical ophthalmic melt-cast
films for the inhibition of P-gp/Mrp1 activity in the blood ocular barriers to improve
blood ocular penetration of substrate chemotherapeutic drugs.
3

Development, quality control, and in vivo evaluation of protransfersomes gel formulation for
improved and prolonged ocular drug delivery through eyelid application.

5

CHAPTER 2
ION SENSITIVE IN SITU HYDROGELS OF ADVANCED NATAMYCIN LOADED
VESICULAR SYSTEMS FOR IMPROVED AND PROLONGED OCULAR
PHARMACOTHERAPY
2.1. Introduction
Despite advancement in the field of pharmaceutical technology, effective topical ocular drug
delivery is still a complicated task for formulation scientists due to the complex anatomical,
physiological and formulation constraints (16-18). Beside various protective ocular barriers, short
pre-corneal residence and poor corneal permeability are the key factors contributing to low ocular
bioavailability (< 5%) of the therapeutics instilled as conventional ophthalmic dosage forms (14,
16-19). The increased lacrimation, reflux blinking and nasolacrimal drainage accounts for the rapid
elimination of the drugs from the cul-de-sac (17,18). Various formulations like ocular ointments,
hydrogels, polymeric or ion-exchange resin based topical ocular inserts and in situ gel systems
have been reported to improve the residence of the drugs in the pre-corneal space (20-23). In situ
hydrogels have better patient compliance unlike ocular ointments and inserts which causes blurred
vision and grittiness influenced distressed blinking (22,24,25). The in situ gel systems are solutions
which undergo phase transition to form viscoelastic hydrogel in the ocular milieu in response to
the temperature, pH, electrolytes or ions and photo radiation (22,24,25). Due to the abundance of
electrolytes in tear fluid, the ion or electrolyte sensitive in situ hydrogel formation is triggered at
lower polymer concentrations with respect to that induced by other stimuli (26,27).
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The distinct anatomical features of the cornea, with hydrophilic stroma sandwiched
between lipophilic epithelium and endothelium, restricts the penetration of hydrophilic and
lipophilic drugs into the deeper ocular tissues [16-19, 28]. Numerous lipid/polymeric nanoformulations such as solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC),
polymeric nanoparticles (PN), micelles and phospholipid or non-ionic surfactant based vesicles
have shown success in enhancing the transcorneal drug permeability (29-34). The combination of
in situ gel systems and nanocarriers offers improved tear/corneal surface contact time and corneal
permeability of the drugs (35). Several pH and/or temperature triggered in situ gel forming systems
of SLN, polymeric nanoparticles, nanoemulsions, liposomes and niosomes have been successfully
investigated as suitable ocular drug delivery platforms (35-39).
In recent years, advanced vesicular systems, bilosomes and transfersomes, have emerged
as potential carriers for improved oral, nasal and/or transdermal delivery of small and large
molecules due to their ultra-deformable and flexible properties (40-42). The inclusion of the
amphiphilic bile salt (bilosomes) or hydrophilic edge activator (transfersomes) in the vesicle
bilayer allows bilosomes and transfersomes to penetrate through the intercellular lipid layers of
intact biological membranes, such as skin, nasal mucosa and intestine (41-44]). Considering these
advantages, a few studies investigated the suitability of bilosomes and transfersomes for improved
ex vivo corneal permeability of a lipophilic molecule (42,44). To the best of our knowledge,
bilosomes and transfersomes ion sensitive in situ hydrogel forming systems have not been
investigated till date.
In this study, we report the fabrication and evaluation of ion sensitive in situ hydrogels of
natamycin (NT)-loaded bilosomes (NB) and transfersomes (FN) for improved ocular
pharmacotherapy. NT, a macrolide polyene antifungal agent, is the only commercially available
7

ophthalmic product (Natacyn® (NT 5% w/v suspension)) approved by US-FDA for treating fungal
keratitis and other fungal infections (45). Due to poor aqueous solubility, limited corneal
permeability and low precorneal residence time of NT, current therapy requires multiple dosing (a
drop every 1-2h) for several weeks (4-6 weeks) to attain and/or maintain therapeutic concentrations
at the desired site (45,46). Hence, there is a need to develop a delivery system, with improved NT
corneal permeability and prolonged drug levels in the ocular sites, for improved patient
compliance. A few literature reports described improved NT levels in the tear and prolonged in
vitro corneal drug permeability from mucoadhesive nanoparticles and niosomes thermosensitive
in situ gels, respectively [39,47]. However, there are no reports on the ocular disposition of NT or
any other drug from topically instilled bilosomes and transfersomes in situ gels.
Thus, for the first time, the ocular disposition of ion sensitive in situ hydrogel forming system
of NB and FN are evaluated in the New Zealand male albino rabbits.
2.2. Materials and Methods
NT was procured from Cayman Chemical (Ann Arbor, MI, USA). Sodium taurocholate (ST) was
obtained from Biosynth International, Inc. (Itasca, IL, USA). Phospholipon 90H (PL) was procured
from Lipoid, LLC (Newark, NJ, USA), Kolliphor TPGS (D-alpha tocopheryl polyethylene glycol
1000 succinate) (T) was obtained from BASF Corporation (NJ, USA), (Sorbitan monostearate
(Span 60 (S60)) and MTT reagent (Methylthiazolyldiphenyl-tetrazolium bromide) were received
from Sigma Aldrich (St. Louis, MO, USA. Cholesterol (CH) was procured from Alfa Aesar (Ward
Hill, MA, USA). Gelan Gum (G) and Xanthum gum (X) were purchased from MP Biomedicals,
LLC (Santa Ana, CA, USA). DMEM/F-12 (Dulbecco's Modified Eagle Medium/Nutrient Mixture
F-12) was procured from Mediatech, Inc. (A Corning Subsidiary Manassas, VA). Glycerin,
Amicon® Ultracentrifugal filter devices with regenerated cellulose membrane (molecular weight
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cut off 100 kDa), high performance liquid chromatography (HPLC) - grade solvents, and other
chemicals (analytical grade) were supplied by Fisher Scientific (Hampton, NH, USA). Whole eyes
of male albino New Zealand rabbits were obtained from Pel-Freez Biologicals (Rogers, AR). Male
albino New Zealand rabbits were procured from Harlan Labs (Indianapolis, IN).
2.2.1. Quantification of natamycin
The NT content in all the samples was determined with HPLC-UV (ultraviolet) method, as
reported earlier, with minor modifications (48). In brief, a mobile phase of acetonitrile and 0.02 M
potassium dihydrogen phosphate (30:70 % v/v) mixture (pH 5.5) was pumped through a
phenomenex Luna® C18(2) 100 Å column (4.6 mm x 250 mm; 5µ particle size), at a flow rate of
1.0 mL/min, by Water 600 controller pump in HPLC system. A 20 µL sample was injected by
Waters 717 plus Autosampler into the mobile phase and the column eluent was monitored at
λmax (detection wavelength) of 304 nm using Waters 2487 Dual λ Absorbance detector. The
absorbance peaks were recorded with the help of Agilent 3395 Integrator.
2.2.2. Preparation of natamycin bilosomes and in situ gel formulations
The film hydration technique was employed to prepare the natamycin bilosomes (NB) (37,49).
Briefly, in 20 mL of organic solvent mixture of chloroform, ethanol and methanol (7:1:2),
accurately weighed quantities of lipid mixture (210 or 230 µM of S60 and CH taken in 2:1, 1:1
and 1:2 molar ratios) and drug were dissolved in a round bottom (RB) flask. The RB ﬂask was
then mounted onto a rotary ﬂash evaporator (Laborota 4000, Heidolph, Germany) operated at 200
rpm for 30 min at 45 ± 5°C to evaporate the organic solvent, under vacuum, leaving a thin film of
lipid on the wall of the flask. The lipid film was dried in vacuum oven at 40°C for 2h and then
hydrated with the deionized water (8-10 mL) containing ST (20 or 40 µM) and glycerin,
maintained at 60 ± 5°C, to form NB with vigorous shaking. Further, the NB was sonicated with
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probe sonicator (Vibra-Cell™ Ultrasonic, Sonics and Material INC., CT, USA) for 5 min with
pulse on for 20 secs and off for 40 secs at 30 % amplitude.
The NB in situ gel NBG or NBX formulations were obtained by adding 8 mL of NB 2 to
2 mL of G or X dissolved in deionized water (60 ± 5°C). The formulations were allowed to cool
to room temperature and stored in screw-capped glass vials until further evaluation. The
composition of the NB and NBG or NBX formulations are presented in Table 2.1.
2.2.3. Preparation of natamycin transfersomes and in situ gel formulations
The NT transfersomes formulations (FN) were prepared by the film hydration technique (42,49).
Accurately weighed quantities of PL, S60, TPGS and NT were dissolved in 20 mL of organic
solvent mixture (chloroform, ethanol and methanol (7:1:2)), in a round bottom (RB) flask (Table
2.2). The RB ﬂask was then mounted onto a rotary ﬂash evaporator (Laborota 4000, Heidolph,
Germany) operated at 200 rpm for 30 min at 45 ± 5°C to evaporate the organic solvent, under
vacuum, leaving a thin residual lipid film on the flask wall. The lipid film was dried in vacuum
oven at 40°C for 2h and then hydrated with the deionized water (8-10 mL) containing glycerin,
maintained at 60 ± 5°C, to form transfersomes with vigorous shaking. Further, the FN was
sonicated with probe sonicator (Vibra-Cell™ Ultrasonic, Sonics and Material INC., CT, USA) for
5 min with pulse on for 20 secs and off for 40 secs at 30 % amplitude.
The FN in situ gel formulations (FNG) were obtained by adding 8 mL of FN 2 to 2 mL of G
dissolved in deionized water (60 ± 5°C). The formulations were allowed to cool to room
temperature and stored in screw-capped glass vials until further evaluation. The composition of
the FN and FNG formulations are presented in Table 2.2.
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2.2.4. Particle size, zeta potential and polydispersity index measurement
The mean particle size (PS) and polydispersity index (PDI) of the NB, NBG, NBX, FN and FNG
formulations were determined by dynamic light scattering using Zetasizer Nano ZS Zen3600
(Malvern Instruments, Inc. UK). Samples were suitably diluted with filtered double distilled water
(0.2 μm nylon filter) and analysis was performed at 25°C and 173° angle of detection using a
helium-neon laser of 633 nm, in disposable clear cells. Zeta potential (ZP) measurements were also
carried out at 25°C using the laser Doppler velocimetry function of the same instrument.
2.2.5. Drug Content and Entrapment Efficiency
The drug content was determined by extracting the NT from the formulations using methanol and
190-proof alcohol (70:30 %v/v) then centrifuged (AccuSpin 17R centrifuge, Fisher Scientiﬁc,
USA) at 13,000 rpm for 20 min. The supernatant was separated, appropriately diluted and
quantified for the drug content by HPLC.
The percentage drug entrapment efficiency (% EE) was determined by estimating the free NT
concentration in the dispersion medium using ultra-filtration technique. In brief, 500 μL of each
formulation was added to the sample reservoir of the Amicon Ultra-centrifugal filter device
(Molecular weight cutoff of 100 kilo Daltons) (Fisher Scientiﬁc, USA) and centrifuged at 5,000
rpm for 10 min (AccuSpin 17R centrifuge, Fisher Scientiﬁc, USA). The NT content in the aqueous
filtrate was evaluated by HPLC. The % EE was calculated from the Eq. (1). The experiment was
carried out in triplicate.
%EE

100

Where Wi =total drug content, and Wf =amount of free drug in aqueous phase.
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(1)

2.2.6. In vitro gelation behavior of NB and FN in situ gels
The gelling capacity of bilosomes (NBG or NBX) and transfersomes (FNG) in situ gel
formulations was visually evaluated by determining the gel formation time (GT) and residence
time (GRT) of intact gel without dissolution or breaking (39,50). Briefly, 50 µL of NBG or NBX
and FNG formulations was dropped into a separate glass vials with 2 mL of freshly prepared
simulated tear fluid (STF) and maintained at 34 ℃ in a shaking water bath (Precision™, Fisher
Scientiﬁc, USA) operated at 100 rpm for 12h. The time taken for the transformation of sol-to-gel
by NBG or NBX and FNG formulations was recorded as the gel formation time (GT). Each vial
was visually inspected every hour and the time required for the gel to dissolve or break was
recorded as the intact gel residence time (GRT).
2.2.7. Rheological studies
The viscosity of the NB 2, NBG, NBX, FN 2 and FNG formulations were measured on Brookfield
cone and plate viscometer (LVDV-II+ Pro Viscometer, Middleboro, USA). Briefly, 500 µL of
each formulation was placed in the cup plate, and the gap between cone and plate was adjusted.
The samples in the cup were maintained at 25°C using a circulating water bath. A CP-40
Cone/Spindle was operated at 0.1, 1 and 10 rpm and the viscosity was recorded from Rheocalc
software. To determine viscosity of the hydrogels, 500 µL of mixture of bilosomes in situ gel or
transfersomes in situ gel formulations and STF (50:7) was placed in cup plate and similar
procedure was repeated to record viscosity (n=3) (37).
2.2.8. Texture analysis
The adhesive strength of hydrogels obtained from NBX, NBG and FNG formulations were
evaluated with TA.XT2i texture analyzer (Texture Technologies Corp. NY. USA) set to the
compression mode (51). The hydrogels were placed in soft matter holder (TA-275) positioned
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below the acrylic cylindrical probe (1-in. diameter (TA-3)) which was then lowered into the
product (1mm distance from the surface) at a test-speed of 0.5 mm/s with 3 g trigger force. An
acquisition rate of 500 points/sec was selected and the texture analysis was conducted at room
temperature (n=3).
2.2.9. Transmission electron microscopy
The morphology of the vesicles in the NB 2, NBG 2, FN 2 and FNG 3 formulations were evaluated
by transmission electron microscopy (TEM) (JEOL JEM1200EX II electron microscope) as per
the published protocol with minor modifications (52). Briefly, the formulations were centrifuged
for 1h at 25,000 rpm and 15°C (SORVALL, WX Ultra Series Centrifuge, USA) to separate the
bilosomes and transfersomes pellets which were then resuspended in 5ml deionized water and
recentrifuged (as mentioned earlier). This step is repeated 3 times to wash out any soluble
impurities. The resuspended bilosomes and transfersomes were centrifuged for 5min at 2000 rpm
(15°C) (Eppendorf AG centrifuge, Hamburg, Germany), to separate the aggregates/insoluble
impurities, and the clean vesicular suspensions were then diluted 1:100 with deionized water. 2 μL
of the diluted suspension was placed on 400 mesh copper grids covered with Formvar film
(Electron Microscopy Sciences EMS, Hatfield, PA, USA). The grids were allowed to dry overnight
in a desiccator and then examined by TEM.
2.2.10. Fourier transform infrared spectroscopy (FTIR)
The infrared spectra of drug, sodium taurocholate, phospholipon 90H, TPGS, cholesterol, span 60
NBG 2 and FNG 3 samples were recorded using Cary 660 series FTIR (Agilent Technologies,
USA) to understand the chemical compatibility between the drug and excipients.
2.2.11. Stability studies
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The NB 2, NBG 2, FN 2 and FNG 3 formulations were taken in glass vials, wrapped in aluminum
foil and stored at 4°C and 25°C for 60 days. Their physical and chemical stability, on storage, were
evaluated by withdrawing the samples at definite time intervals (0, 30 and 60 days) and analyzing
the particle size, PDI, zeta potential, % EE and drug content as described earlier.
2.2.12. In vitro cytotoxicity
In vitro cytotoxicity of NB 2, NBG 2, FN 2, FN 5 and FNG 3 formulations were evaluated by the
methyl thiazolyl tetrazolium (MTT) assay. Normal saline and triton x 100 served as negative and
positive controls for the experiment respectively. The assay was carried out in 96-well plates
(Costar 3596, Corning Inc., Corning, NY). Briefly, 100 μl of the human corneal limbal epithelial
(HCLE) cells were plated at a concentration of 15x104 cell/mL, and incubated in an incubator at
37°C with 5% CO2 for 24h in culture medium (DMEM/F-12 50:50, with 10% calf serum, and 1%
penicillin/streptomycin). Then, 100 μl of the diluted formulations, negative control (normal
saline), NB 2, NBG 2, FN 2, FN 5, FNG 3 and positive control (triton X 100)) (i.e., 50 μl
formulation + 50 μl of DMEM/F-12 50:50 Medium) was added to each well. After 24h incubation,
the formulations were removed, and the cells were washed twice with the culture medium to
remove all traces of the formulations. 100 μl of MTT reagent (1 mg/ml in culture medium without
serum) was added to each well and the plates were incubated at 37°C for 4h. During the incubation,
the active enzymes (mitochondrial reductase) of the viable cells converted the yellow MTT dye
into purple formazan crystals. After incubation, the medium was removed and 100 μl DMSO was
added to each well to dissolve the formazan crystals and the intensity of color was assessed at 570
nm with µ-Quant universal microplate spectrophotometer (Bio-Tek Instruments, Inc. Winooski,
VT).
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2.2.13. In vitro corneal permeation studies
In vitro transcorneal permeation studies were performed in the corneas separated from rabbit whole
eyes shipped overnight in Hanks balanced salt solution (over wet ice) from Pel-Freez Biologicals.
They were used immediately upon receipt. To confirm the secure mounting between the donor and
receiver chambers of diffusion cell during the study period, corneas were excised with some scleral
portion. They were placed on Valia-Chien cells (PermeGear, Inc®), maintained at 34°C, with the
endothelial side facing receiver chamber while the epithelial side facing the donor chamber. 200
µL of control (Natacyn ®), NB 2, NBG 2, FN 2, FN 5 and FNG 3 formulations were added to the
individual donor chambers. 50 µL of DPBS was placed in the donor chamber holding 200 µL of
NBG 2 or FNG 3 formulation to ensure the hydrogel formation. The Natacyn ® suspension was
diluted to obtain 0.1% w/v NT, equivalent to that in NB 2 and NBG 2 formulations. The receiver
chamber was filled with 5 mL of DPBS (pH 7.4) with 2.5% w/v of RMβCD medium. At
predetermined time points, an aliquot of 600 µL was withdrawn from the receiver chamber and
replenished with equal volume of fresh medium to maintain the constant volume, until 3h. Samples
were stored at −20°C until further analysis by HPLC.

2.2.14. Data analysis
The transcorneal permeation parameters across rabbit cornea such as the cumulative amount of
drug permeated (Mn), steady state flux (J) and the apparent permeability coefﬁcient (Papp) were
calculated as per the earlier reports (53). The cumulative amount of NT permeated across the
cornea was determined using the equation Eq. (2).
∑

(2)

Where: n indicates sampling time point (n = 1, 2, 3….8 corresponding to 15, 30, 45….180 min
respectively); Vr and VS represents the volume of the medium in the receiver chamber (mL) and
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the volume of the sample collected at the nth time point (mL); and Cr(n) specifies the concentration
of the drug in the receiver chamber medium at nth time point (µg/mL).
The rate of NT transported through the rabbit cornea was computed from the slope of the
cumulative amount of NT permeated vs. time (t) plot. The steady-state flux (SSF) (J) of natamycin
was calculated according to the following equation (Eq. (3)) (30):
/ " /#

(3)

Where M and A designates the cumulative amount of drug transported and the surface area of the
cornea utilized in the experiment (0.636 cm2).
The transcorneal permeability of NT was determined from the ratio of steady state flux (J) and
amount of drug taken in the donor chamber (Cd) (Eq. (4)) (30,53).
$%&&
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Further, the enhancement ratio (ER) was determined from the ratio of flux (J) of natamycin from
bilosomes (NB 2) or bilosome in situ gel (NBG 2) or transfersomes (FN 2 or FN 5) or
transfersomes in situ gel (FNG 3) formulation and control formulation.

2.2.15. Corneal Histology studies
The corneal histological evaluation was performed on the corneas utilized in the in vitro
transcorneal permeation studies. At the end of the study, corneas were fixed with 4%
paraformaldehyde for 24 h, embedded in paraffin wax and were sliced into 5-μm cross sections
using a microtome (American Optical® 820 Rotary Microtome). The tissue sections were mounted
on a slide and dried overnight in an oven. The slide was washed with xylene to remove the paraffin
and the tissue was hydrated by washing with alcohol and water. The tissue was stained with nuclear
dye Gill III hematoxylin (StatLab medical) by rinsing for 10 min and later counterstained with
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eosin. Finally, these slides were washed in running water, alcohol, and xylene. A cover slip was
placed on the tissue section, examined under Nikon Eclipse 800 microscope and images were
captured using PictureFrame 3.0 software (Optronics) to observe morphological changes in cornea,
if any.

2.2.16. Ocular distribution study
The ocular distribution study was carried out in conscious male New Zealand albino rabbits. Prior
to the study, the animals were allowed free access to food and water. The experiment was
performed according to the approved protocols of the University of Mississippi Institutional
Animal Care and Use committee and Association for Research in Vision and Ophthalmology
(ARVO) statement. The rabbits were divided into 5 groups based on the formulation they were
treated with and represented as control (Natacyn ®), NB 2, NBG 2, FN 2 and FNG 3 groups. 50
µL of Natacyn ® or NB 2 or NBG 2 or FN 2 or FNG 3 formulation was topically administered in
the cul-de-sac of the right eye of each rabbit in the corresponding group. At the end of 2 h and 6
h post treatment, rabbits (n=4) were anesthetized with intramuscular injection of ketamine and
xylazine combination and euthanized with an excess amount of pentobarbital injected through a
marginal ear vein. The treated eye was washed thoroughly with ice cold IPBS and enucleated
immediately. The ocular tissues were carefully separated, weighed and stored at -80 °C until
analysis.

2.2.17. NT extraction from ocular tissue matrix
Protein precipitation technique was employed for the extraction of NT from the ocular tissue
matrix. Briefly, tissues such as cornea, sclera, iris ciliary (IC), retina-choroid (RC) were taken in
separate Eppendorf tubes and cut into small pieces followed by the addition of 1 mL ice cold
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methanol with 0.1% w/v formic acid to precipitate tissue proteins. The proteins in the aqueous
humor (AH) (200 µL) and vitreous humor (VH) (500 µL) were precipitated by adding 200 µL and
500 µL of ice-cold acetonitrile with 0.1% w/v formic acid respectively. All the Eppendorf tubes
were vortexed for 30 seconds, allowed to stand at room temperature for 15 min and kept under
sonication in bath sonicator (Fisher Scientiﬁc, USA) for 10 min to extract the drug into solvent.
These samples were centrifuged at 13,000 rpm for 30 min, the supernatant was collected in the
separate vials and stored at -80 oC until the analysis. The NT content in the supernatant solutions
were estimated by injecting an aliquot of 100 µL into the HPLC operated with the chromatographic
conditions described earlier (48). The column eluent was monitored at λmax (detection wavelength)
of 304 nm using Waters 2487 Dual λ absorbance detector, and the sensitivity was set at 0.05 AUFS
at room temperature. The NT was quantified using standard calibration plots constructed with the
concentration range of interest in various ocular tissues. The limit of detection and quantiﬁcation
in various ocular tissues were 10 and 20 ng/mL, respectively. The standard curves in all the ocular
tissues were linear with a coefficient of determination (r2) ≥ 0.95.

2.2.18. Statistical analysis
The data obtained were subjected to one-way analysis of variance (ANOVA) and the statistical
signiﬁcance of difference between formulations was calculated by Tukey’s post hoc HSD (version
5.00; GraphPad Software, San Diego California). A ‘p’ value less than 0.05 was set to represent
the statistically signiﬁcant difference.
2.3.

Results and Discussion

NB and FN formulations were successfully fabricated by thin-film hydration technique coupled
with probe sonication. Since the selection of vesicle forming components is critical to obtain the
stable vesicles with high drug entrapment, S60 and PL were selected as vesicular components in
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bilosomes and transfersomes, respectively (41-44). Earlier reports suggested the formation of
small size niosomes, a nonionic surfactant vesicle, with S60 and stable liposomes with the
phospholipon 90H (PL), due to the absence of unsaturated bonds in the fatty acid tails which leads
to oxidation of phospholipid (42,54).
2.3.1. Physicochemical properties of NB
The physicochemical properties of bilosomes such as particle size (PS), polydispersity index
(PDI), zeta potential (ZP) and drug entrapment (% EE) are dependent on the proportion of S60-toCH and the bile salt (ST) (45,55). Hence, in the present study, the influence of cholesterol and the

Table 2.1: Composition and physicochemical properties of natamycin bilosomes (mean ± SD; n=3).
Formulation

Component/Evaluation
parameter

NB 1

NB 2

NB 3

NB 4

NB 5

NB 6

2:1

1:1

1:2

2:1

1:1

1:2

Span 60 (mg)

66

50

33

60

45

30

Cholesterol (mg)

30

44

59

27

41

54

ST (mg)

10

10

10

21

21

21

Molar ratio (Span
60:Cholesterol)

PS (nm)
PDI
ZP (mv)

330.1 ± 21.6 235.0 ± 05.2 287.9 ± 12.1 380.4 ± 27.9 303.3 ± 16.0 348.2 ± 13.1
0.30 ± 0.10 0.20 ± 0.01 0.23 ± 0.13 0.43 ± 0.23 0.28 ± 0.09

0.31 ± 0.03

-45.4 ± 4.5

-66.3 ± 9.1

-47.0 ± 1.5 -51.1 ± 3.3 -67.2 ± 2.6 -69.0 ± 1.5

% EE

78.6 ± 4.1

93.7 ± 4.3

84.1 ± 2.6

70.1 ± 3.6

81.4 ± 2.5

74.1 ± 3.5

Drug content (%)

96.7 ± 1.1

96.2 ± 2.0

96.1 ± 2.5

97.9 ± 4.1

90.1 ± 7.2

95.6 ± 1.2

pH

6.2 ± 0.9

6.4 ± 0.3

6.3 ± 0.1

6.5 ± 0.2

7.1 ± 0.2

6.6 ± 0.3

- NB and ST indicates natamycin loaded bilosomes and sodium taurocholate, respectively.
- PS, ZP, PDI and % EE represents particle size, zeta potential, polydispersity index and % entrapment
efficiency respectively.
- Total 250 µM of lipid mixture (including sodium taurocholate) was used in all preparations.
- 10 mL of each formulation contains 10 mg of natamycin and 225 mg of glycerin.

bile salt on these parameters were investigated by varying the S60-to-CH molar ratio and ST
quantity, respectively, keeping overall lipid content 250 µM. The NT content in all the NB
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formulations (pH 6.2 -7.1) was in the range of 90.1 ± 7.2% to 97.9 ± 4.1% (Table 2.1). The NB
formulations showed PS ranging from 235.03 ± 05.29 nm to 380.43 ± 27.94 nm with a PDI of 0.20
± 0.01-0.43 ± 0.23, ZP of -45.41 ± 4.54 mV - -69.03 ± 1.57 mV and % EE of 70.12 ± 3.66 % –
93.75 ± 4.32 % (Table 2.1).
2.3.2.1. Effect of cholesterol
The PS and % EE of NT in bilosomes appeared to be dependent on the CH composition. It was
noticed that the PS of bilosomes decreased as the CH content increased in the formulations (NB 1
to NB 2 or NB 4 to NB 5) (Table 2.1). Generally, CH interacts with the hydrophobic tails of the
lipids in the vesicle bilayer and controls the packing and rigidity of the vesicles (56). Thus, the
decrease in PS can be attributed to the increased interactions of CH and S60 leading to close
packing of the bilayers in the bilosomes. The % EE increased proportionately with the CH
concentration in the formulations NB 1 to NB 2 or NB 4 to NB 5 suggesting effective intercalation
of NT within the bilayer with increased hydrophobic interactions and reduced leakage of drug from
rigid bilosomes (Table 2.1) (56,57). Interestingly, further increase in the CH concentration in the
formulations (NB 3 or NB 6) resulted in higher PS and lower % EE (Table 2.1). This can be
attributed to the perturbation of bilayer structure by the accommodation of excess cholesterol and
thereby leading to the expulsion of drug from the vesicles (55,57).
2.3.2.2. Effect of bile salt
Consistent with the earlier reports, the PS, PDI, ZP and % EE of the bilosomes were influenced
by the amount of bile salt (40,45,58). With a steroid like structure, ST, a salt of taurocholic acid
(bile acid), resides in the bilayer of the bilosomes imparting negative ZP due to its anionic nature
(44,58). The PS, PDI and ZP of the formulations with 40 µM (21 mg) ST (NB 4 – NB 6) were
higher compared to the bilosomes with 20 µM (10 mg) ST (NB 1- NB 3), at similar molar ratio of
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S60 and CH (Table 2.1). These results corroborate with earlier literature reports which
demonstrated the increased PS and PDI because of the repulsion between the bilayers of the
vesicles due to the greater negative charge (ZP) at higher concentration of ST (59). Moreover, the
accommodation of extra ST in the bilayers can increase the bulkiness of bilosomes resulting in
increased particle size and the excess of amount of ST forms micelles in the dispersion medium
thereby resulting in increased PDI (60,61). Strikingly, the %EE of NT in the bilosomes, with same
molar ratio of S60 and CH, decreased with the increased ST quantity (Table 2.1). This drop in
%EE, at higher concentration of ST, is attributed to the leakage of the entrapped drug from the
bilosomes owing to the fluidization of vesicle bilayer by bile salt micelles (44).
The NB 2 formulation showed uniformly distributed bilosomes (235.0 ± 05.2 nm) in the
colloidal dispersion (PDI: 0.20 ± 0.01) with negative ZP (-47.0 ± 1.5 mV), and higher % EE (93.7

Fig. 2.1: Transmission electron micrographs (TEM) depicting the layered morphology of bilosomes in A)
NB 2 and B) NBG 2 and transfersomes in C) FN 2 and D) FNG 3.

± 4.3 %). Additionally, TEM image revealed layered nanoparticles confirming the vesicular
structure of the bilosomes in the NB 2 formulation (Fig. 2.1A). Hence, this formulation was
optimized and used in further investigations and for the preparation of in situ gel formulations.
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2.3.2. Physicochemical properties of FN
The impact of phospholipid and the TPGS on natamycin transfersomes PS, PDI, ZP and %
EE were investigated by varying the PL-to-S60 molar ratio and T quantity, respectively, keeping
overall lipid content 250 µM. The NT content in all the FN formulations (pH 6.1 -6.9) was in the
range of 94.7 ± 7.2% to 97.9 ± 4.1% (Table 2.2).
The FN formulations showed PS ranging from 137.3 ± 3.0 nm to 192.1 ± 8.6 nm with a
PDI of 0.20 ± 0.01-0.41 ± 0.1, ZP of -13.2 ± 2.6 mV - -20.9 ± 3.7 mV and % EE of 69.4 ± 2.4 %
– 91.4 ± 2.7 % (Table 2.2).
It was noticed that the PS, PDI and % EE of NT in transfersomes were influenced by the molar
ratio of PL:S60. The FN obtained from equimolar composition of PL and S60 (FN 2 and FN 5)
Table 2.2: Composition and physicochemical properties of natamycin transfersomes (mean ± SD; n=3).
Formulation

Component/Evaluation
parameter

FN 1

FN 2

FN 3

FN 4

FN 5

FN 6

2:1

1:1

1:2

2:1

1:1

1:2

91

122

136

82

109

123

Span60 (mg)

52

36

27

46

31

23

T (mg)

10

10

10

50

50

50

Molar ratio
(Phospholipon
90H:Span60)
Phospholipon 90H
(mg)

PS (nm)

192.1 ± 8.6

145.2 ± 2.9 165.2 ± 2.9 171.4 ± 3.9

137.3 ± 3.0

158.2 ± 6.1

PDI

0.33 ± 0.12

0.20 ± 0.01

0.21 ± 0.1

0.41± 0.1

0.32 ± 0.01

0.40 ± 0.3

ZP (mv)

-14.4 ± 2.4

-17.0 ± 1.5

-20.9 ± 3.7

-13.2 ± 2.6

-15.3 ± 1.5

-18.3 ± 3.1

% EE

74.1 ± 4.2

84.8 ± 4.8

69.4 ± 2.4

80.7 ± 1.3

91.4 ± 2.7

75.4 ± 1.5

Drug content (%)

94.7 ± 2.2

95.2 ± 1.6

97.1 ± 3.0

98.1 ± 1.1

98.3 ± 2.3

95.6 ± 1.2

pH

6.3 ± 0.4

6.1 ± 0.7

6.9 ± 0.1

6.2 ± 0.5

6.1 ± 0.4

6.9 ± 0.1

- FN and T indicates natamycin loaded transfersomes formulation and TPGS, respectively.
- PS, ZP, PDI and % EE represents particle size, zeta potential, polydispersity index and % entrapment
efficiency respectively.
- Total 250 µM of lipid mixture was used in all preparations.
- 10 mL of each formulation contains 10 mg of natamycin and 225 mg of glycerin.
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were small compared to those resulted from 2:1 and 1:2 molar proportion (Table 2.2). This could
be attributed to the stronger hydrophobic interactions between the nonionic surfactant (S60) and
fatty acid chains of phospholipid (PL) in the vesicle bilayer which determines the critical packing
of the vesicles (39). The higher % EE of NT in transfersomes with equimolar proportion of PL and
S60 (FN 2 or FN 5) suggested the effective intercalation of NT within the bilayer with increased
hydrophobic interactions leading to closely packed transfersomes with no or low drug leakage
(Table 2.2) (39,40). The higher PS and lower % EE of transfersomes obtained from 2:1 and 1:2
molar proportion of P and S60 could be due to either low hydrophobic interactions between
vesicular components leading to poor packing of the bilayers or the perturbation of bilayer
structure by the accommodation of excess of P and thereby leading to the expulsion of drug from
the vesicles (39,40). Interestingly, the proportion of edge activator (T) in the structure of
transfersomes influenced the PDI and % EE, but not PS and ZP, of these vesicles (Table 2.2). At
any given molar proportion of PL:S60, the EE and PDI of the transfersomes increased with
increase in the amount edge activator (T) (table 2.2). This higher EE could be due to the formation
drug entrapped micelles by the excess amount of T that leaked into the dispersion medium from
bilayer of the transfersomes and, thereby resulted in increased PDI (43,44).
The FN 2 (145.2 ± 2.9 nm) and FN 5 (137.3 ± 3.0 nm) formulations showed uniformly
distributed transfersomes in the colloidal dispersion (PDI: 0.20 ± 0.01) with higher % EE ((FN 284.8 ± 4.8 %)- FN 5 (91.4 ± 2.7 %)). Additionally, TEM image revealed layered nanoparticles
confirming the vesicular structure of the transfersomes in the FN 2 formulation (Fig. 2.1C).
2.3.3. Evaluation of NB and FN in situ gel formulations
The NB in situ hydrogel systems (NBG/NBX) were derived by introducing the NB 2 formulations
into the solution comprising gellan gum/xanthum gum, anionic polysaccharide polymers, as ion
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sensitive gelling agents. Similarly, the FNG formulations were prepared by incorporating FN 2
preparation into the solution with gellan gum. The physiochemical properties of bilosomes in the
in situ gel formulations (NBG and NBX) were similar to NB 2 preparation, and the properties of
transfersomes in the FNG formulations were no different to the FN 2 preparation, confirming no
interactions of gelling agents with vesicular systems. Several literature reports have successfully
demonstrated the formulation of nanoparticles or nanoemulsion loaded in situ gels using these
gelling agents as they crosslink in the presence of electrolytes to form hydrogel matrix with higher
pore size facilitating the movement of nanoparticles through the gel (26,35-39). The tested
concentrations of gelling agents were below the limits specified in the inactive ingredients database
from US FDA (62). Owing to the thickening property of gellan gum and xanthum gum, it is
essential to measure the viscosity of the in situ gel preparations as it determines the free flow of
the formulation from the container ensuring the ease of administration. A viscosity of 25-50 cP is
most common for ophthalmic solutions (63). The formation, residence time, viscoelastic behavior
and adhesive property of the hydrogels are critical parameters in deciding the pre-corneal residence
and shear thinning pseudoplastic behavior for comfort in the eye while blinking (27,35,37).
However, these parameters depend on the kind of gelling agent. Hence, this study focused on the
influence of the two most commonly used ion sensitive gelling agents on the critical properties of
in situ gel formulations.
2.3.3.1.

Impact of type of gelling agent

The evaluation parameters of the bilosomes in situ gel formulations (NBG and NBX) and
transfersomes in situ gel systems (FNG) are represented in the Table 2.3 and Table 2.4,
respectively. The viscosity of the formulations (NBG or NBX) increased with the concentration of
gelling agents confirming their thickening property (Table 2.3). At any given concentration of
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gelling agent, the viscosity of the NBG formulations were lower compared to that observed in
NBX formulations (Table 2.3). These results were in accordance with the previous reports
explaining the higher viscosity of the xanthan gum due to the formation of helical structures via
hydrogen bonding resulting in the immobilization of water (64). Additionally, the increased
Table 2.3: Composition and characterization of NB in situ hydrogel formulations (mean ± SD; n=3).
Component/Evaluat
ion parameter
Molar ratio (Span
60:Cholesterol)

Formulation
NB 2

NBG 1

NBG 2

NBG 3

NBX 1

NBX 2

NBX 3

1:1

1:1

1:1

1:1

1:1

1:1

1:1

50
50
50
50
50
50
50
Span 60 (mg)
44
44
44
44
44
44
44
Cholesterol (mg)
10
10
10
10
10
10
10
ST (mg)
-20
30
40
---G (mg)
----20
30
40
X (mg)
Viscosity (cP)
17.1 ± 2.7 24.7 ± 1.5 37.5 ± 2.4 68.3 ± 3.2 39.5 ± 4.1 87.8 ± 2.5 124.2 ± 4.7
(Formulation)
-<5
<5
<5
> 20
> 20
15-20
GT (sec)
-3-4
6-8
>12
<1
1-2
5
GRT (h)
Viscosity (cP)
-- 104.5 ± 1.5 514.9 ± 3.8 1285. 6 ± 6.8 128.9 ± 6.5 220.3 ± 5.7410.6 ± 4.2
(hydrogel)
Work of Adhesion
-0.80 ± 0.01 1.39 ± 0.06 1.31 ± 0.07 0.68 ± 0.02 0.71 ± 0.011.14 ± 0.10
(g. sec)
- NB, NBG, NBX, ST, GT and GRT represents natamycin loaded bilosomes, natamycin bilosome in situ gels
with gellan gum, natamycin bilosome in situ gels with xanthum gum, gel formation time and intact gel
residence time and sodium taurocholate, respectively.
- Total 250 µM of lipid mixture (including sodium taurocholate) was used in all preparations.
- 10 mL of each formulation contains 10 mg of natamycin and 225 mg of glycerin.

intermolecular accumulation of polymer chains because of the high molecular weight of xanthan
gum (~ 2000K Daltons) could be the reason for high viscosity of NBX systems (65). Conversely,
the lower viscosity of the gellan gum formulations (NBG) can be attributed to the formation of
weak double helices associated with the van-der-Waal forces (37). The NBG formulations
immediately (< 5 sec) underwent in situ phase transition and formed hydrogels while the NBX
formulations slowly (≥ 20 sec) formed in situ hydrogels in the STF suggesting the slow or poor
interaction of electrolytes with the xanthan gum compared to the gellan gum (37) (Table 2.3). The

25

intact gel residence time and the viscosity of the hydrogels increased with the increasing proportion
of the gelling agent (Table 2.3). However, at a given concertation of the gelling agent, these
properties were higher for the hydrogels formed from NBG formulations compared to that from
NBX preparations (Table 2.3). Similar findings have been reported in the literature where higher
viscosities/stiffness of the gellan gum based in situ gels was due to the cross-linking of the polymer
chain by the mono/divalent cation mediated aggregates of double helices (66). In contrast, the
lower viscosity/intactness of the hydrogel formed from the NBX formulations can be attributed to
the presence of the trisaccharide side chain in the branched structure of xanthan gum which avoids
Table 2.4: Composition and characterization of FN in situ hydrogel formulations (mean ± SD; n=3).
Component/Evaluation
parameter

Formulation
FN 2

FNG 1

FNG 2

FNG 3

Molar ratio (Phospholipid
1:1
1:1
1:1
1:1
90H:Span60)
122
122
122
122
Phospholipid 90H (mg)
36
36
36
36
Span60 (mg)
10
10
10
10
T (mg)
-10
20
30
G (mg)
Viscosity (cP)
16.8 ± 3.1
18.7 ± 1.5
27.5 ± 1.4
39.6 ± 2.6
(Formulation)
-<5
<5
<5
GT (sec)
-<1
3-4
6-7
GRT (h)
Viscosity (cP)
-94.1 ± 2.5
206.9 ± 4.1
651.3 ± 1.7
(hydrogel)
-0.56 ± 0.05
0.94 ± 0.02
1.33 ± 0.04
Work of Adhesion (g. sec)
- FN, FNG, T, GT and GRT represents natamycin loaded transfersomes, natamycin transfersomes in situ gels
with gellan gum, TPGS, gel formation time and intact gel residence time, respectively.
- Total 250 µM of lipid mixture was used in all preparations.
- 10 mL of each formulation contains 10 mg of natamycin and 225 mg of glycerin.

the cation triggered helix formation leading to low or no cross linking of the polymer (26). The
adhesiveness of the in situ hydrogel is an important factor that determines its contact with the
corneal or scleral surface (38). In this study, the work of adhesion of hydrogels was measured to
understand their adhesive characteristics. The work of adhesion increased with respect to the
concentration of gel forming agent in NBX but similar trend in NBG formulations were seen up
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to the gellan gum concentration of 0.3% w/v. This might be due to the formation of stiff gel with
poor shear thinning behavior, at higher proportion of gellan gum (0.4 %), which could lead to
discomfort in the eye (37). At a given concentration of gelling agent, it was noticed that the work
of adhesion of hydrogels from NBG formulations was high over that from NBX formulations
(Table 2.3). These findings agree with the measured viscosities of the hydrogels and could be
attributed to the structure related differences in cross-linking of the polymer chains of gellan and
xanthan gum (37,64). These results exemplified the superior in situ gelling features of gellan gum,
over xanthan gum. Thus, gellan gum based FN in situ gel systems were further studied. As
observed with the NBG formulations, the FNG formulations showed increasing in situ gelling
behavior (GT), intact gel residence time (GRT), rheological properties (viscosity of FNG
formulations and their corresponding in situ hydrogels), and adhesive properties with increase in
the composition of gellan gum (Table 2.4).
Thus, NBG 2 and FNG 3 formulations which showed acceptable viscosity (37.5 ± 2.4 cp and 39.6
± 2.6 cp, respectively), immediate transition into a hydrogel in the STF which remained intact for
> 6h with superior adhesive property were selected as suitable NB and FN in situ gel systems and
investigated further. Layered nanoparticles seen in the STF with hydrogel suggested that the in
situ gels system did not alter morphometric properties of bilosomes and or transfersomes (Fig. 2.1
B and C).
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2.3.4. Fourier transmission infrared spectroscopy (FTIR)

Fig. 2.2: FTIR spectra of A) sodium taurocholate, B) cholesterol, C) span 60, D) phospholipon 90H, E) TPGS, F)
natamycin, G) NBG 2 and H) FNG 3.

The FTIR spectra of NT, NBG 2 and FNG 3 formulations and other excipients are portrayed in
Figure 2.2. The existence of signature functional group stretching of NT at 3260 cm-1 (NH+3
deformation), 1713 cm-1 (-C=O), 1567 cm-1 (-CH=CH-) and 1266 cm-1 (-C-O-C-) in the FTIR
spectra of NBG 2 and FNG 3 formulations suggested no drug-excipient chemical interactions.
However, the slight shift in the IR bands of NT in NBG 2 and FNG 3 spectra could be due to the
transformation in NT physical state (Fig 2.2).
2.3.5. In vitro cytotoxicity
The cytotoxicity of NB 2, FN 2, FN 5, NBG 2 and FNG 3 formulations in HCLE cells is presented
in Figure 2.3. About 100.5 ± 4.5, 110.7 ± 5.6 and 93.0 ± 6.7 % cell viability was noticed for NB
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Fig. 2.3: Cytotoxicity profile of NB 2, FN 2, FN 5, NBG 2 and FNG 3 formulations in HCLE cells (mean ±
SEM; n=6).

2, NBG 2 and FNG 3 groups, respectively, which were not statistically different from the negative
control group (saline) (Fig. 2.3). The results noted from FN 2 and FN 5 formulations were
significantly different from that observed in negative control group (saline). The positive control
group treated with triton X 100 (1 %), a nonionic surfactant, showed 6.9 ± 2.5 % cell viability (Fig.
2.3). Hence, the drop in % cell viability of the groups exposed to FN formulations (FN 2 and FN
5) could be related with the overall nonionic surfactant (NS) composition (T and S60) in
formulations. The group treated with FN 2 (0.45 % w/v of NS) showed considerably higher % cell
viability (65.7 ± 4.8%) compared to FN 5 (0.86 %w/v of NS) (17.7 ± 5.4%) (Fig. 2.3). Hence, it is
presumed that the higher NS concentration might have attributed to lower % cell viability.
However, no reports in the literature has demonstrated the corneal toxicity of the combination of
S60 and T. The higher % cell viability of FNG 3 group suggested that the in situ gels of FN 2
formulations are well tolerated by corneal epithelial cells (Fig. 2.3). Hence, the cytotoxicity results
of NB 2 and NBG 2 formulations suggest that the optimized bilosomes and its in situ gel
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formulations are well tolerated by corneal epithelial cells and can be explored as a suitable vehicle
for topical ocular drug delivery. Similar literature reports discussed no ocular cytotoxicity with the
vesicular systems containing nonionic surfactants (S60) and/or bile salts (44,55). In addition, a
study outlined no corneal cytotoxicity with the liposomes containing the sodium taurocholate,

Fig. 2.4: In vitro transcorneal A) flux and B) apparent permeability coefficient (Papp) of natamycin from control,
bilosomes, bilosomes in situ gel, transfersomes and transfersomes in situ gel formulations (mean ± SD; n=3). *significantly different from control (p<0.05); ¥-significantly from any formulations group (p<0.05).

whereas formulations containing sodium deoxycholate were toxic to HCE cells (58). In the
cytotoxicity studies, the HCLE cells were exposed to the formulations for 24h. But, most of the
topical ophthalmic formulations will be in contact with cornea for short time due to rapid clearance
from the precorneal space. Thus, to further understand the toxic effects of bilosomes and
transfersomes on cornea anatomy, histology studies were performed on the corneas exposed to the
formulations in corneal transport studies.
2.3.6. Corneal transport studies
The saturation solubility of NT was in the following order: DPBS (2.5 % w/v RMβCD) > DPBS
≥ IPBS > water. Hence, to maintain sink, DPBS (2.5 % w/v RMβCD) was utilized as the release
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medium in the in vitro corneal transport studies. The transcorneal permeability parameters of NT
from control, NB 2, FN 2, FN 5, NBG 2 and FNG 3 formulations are detailed in Figure 2.4. A
significant improvement in the transcorneal flux of drug was observed from NB 2, FN 2, FN 5,
NBG 2 and FNG 3 over that from control suspension (p<0.05) (Fig. 2.4A). An ER of 9.01 and
6.37 transcorneal flux of NT from NB 2/FN 2 and NBG 2/FNG 3 formulations, respectively,
indicated their potential to improve the corneal transport of NT. Further, significantly higher
apparent permeability coefficient (Papp) of NT from NB 2, FN 2, NBG 2 and FNG 3, compared to
control, could be attributed to the improved permeability of these advanced vesicles (p<0.05) (Fig.
2.4B)). These findings verify the previous literature reports, which described the penetration of
bilosomes or transfersomes through intact cornea owing to the fluidization of corneal lipids
(44,58,42,43). In addition, the superior flexibility of these vesicles with bile salt (ST) and edge
activator (T) enables them to permeate across the intact biological membranes (40-43). The lower
transcorneal flux and Papp of NT from NBG 2, compared to NB 2, were consistent with the earlier
reports which suggested the slower release of drug loaded nanoparticles or vesicles from the in
situ hydrogel matrix (p<0.05) (Fig. 2.4) (36,37).
Interestingly, an ER of ~16 fold transcorneal flux of NT from the FN 5 formulation was
seen with apparent permeability coefficient (Papp) 3.9 X 10-5 Cm/s (Fig. 2.4). These results were
significantly superior over those observed from any other formulations (p<0.05). A sudden
increase in the % cumulative drug release, from FN 5 formulation, was noticed after 1h timepoint
(data not shown). These findings suggest that there might be a damage to the corneal structure.
2.3.7. Corneal histology
Corneal histology studies were carried out to access the corneal tissue architecture after the
treatment with NB 2, FN 2, FN 5, NBG 2 and FNG 3 formulations. The histology of corneas
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exposed to DPBS, marketed suspension, NB 2 FN 2, FN 5, NBG 2 and FNG 3 in the in vitro
transcorneal permeation studies are portrayed in Figure 2.5. Normal anatomy of an intact cornea

Fig. 2.5: Histology images of rabbit corneas exposed to A) DPBS, B) control, C) NB 2, D) NBG 2, E) FN 2, F) FN
5, and G) FNG 3 formulations. EP-epithelial layer; BM-Bowman’s membrane; SL- stromal layer.

represents epithelial layer (EP) and stroma layer (SL) separated by Bowman’s membrane (BM),
and descemet’s membrane that separates the stroma from endothelial layer. Any observations like
tear or loss, degeneration or disappearance of epithelial layer, separation of Bowman’s membrane
from epithelial and stroma layers, vacuoles in the stroma layer confirms the damage of corneal
structure. In this study, the corneas exposed to NB 2, FN 2, NBG 2 and FNG 3 formulations did
not show any such signs, suggesting no alterations in the corneal tissue architecture during the in
vitro transcorneal permeability studies (Fig. 2.5). Moreover, the corneas exposed to NB 2, FN 2,
NBG 2 and FNG 3 formulations were not structurally different from those exposed to control
marketed suspension and DPBS (Fig. 2.5) suggesting the corneal compatibility of these advanced
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vesicular systems and their corresponding ion sensitive in situ gel formulations. Similar findings
were reported in the literature which indicated safety of ST and/or nonionic surfactant based
vesicles to ocular sites (37,55,58,42,43).
The loss of epithelial layer on the cornea exposed to FN 5 formulation confirmed that the
transfersomes, prepared with 0.8 % w/v of NS (T and S60), is toxic to the corneal structure and,
hence, showed superior transcorneal permeability characteristics (Fig. 2.5F). These results
corroborate with the observations in the in vitro cytotoxicity studies (Fig. 2.3). Hence, NB 2, FN
2, NBG 2 and FNG 3 formulations were selected for the in vivo performance evaluation.
2.3.8. Ocular disposition studies
Since the performance of pharmaceutical product depends on the drug and other excipients in it,
undiluted Natacyn suspension (5 % w/v natamycin) was used, to exclude the underestimation of
the product efficacy, as a control formulation in the ocular distribution studies. The amount of drug
observed in the ocular tissues of the rabbits at the end of 2h and 6h post treatment with control,
NB 2, FN 2, NBG 2 and FNG 3 formulations are given in table 2.5. To understand the permeability
and prolong delivery of NT from control, NB 2, FN 2, NBG 2 and FNG 3formulations, the mean
dose normalized drug levels in the rabbit ocular tissues were calculated and presented in Figure
2.6.
At the end of 2h, the concentration of NT observed in the cornea and AH of rabbits
administered with control at 50-fold high dose were disproportionately higher by ~13-18 and ~36-fold, respectively, compared to that treated with NB 2, FN 2, NBG 2 and FNG 3 formulations
(Table 2.5). Hence, the mean dose normalized NT concentration in cornea and AH of rabbits
treated with NB 2, FN 2, NBG 2 and FNG 3 formulations were significantly higher, over that seen
in the control group, indicating the improved penetration of
33
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290.1 ± 56.9

2500

Control

212.3 ± 44.2
243.6 ± 22.6

50
50

NBG 2

FNG 2

15.4 ± 1.2

13.0 ± 1.4

ND

ND

249.7 ± 58.1

233 ± 4

ND

ND

490.2 ± 60.6

224.9 ± 33.2

264.5 ± 16.2

632.9 ± 135.9

369.4 ± 64.6

225.3 ± 70.1

IC

126.6 ± 16.2

158.4 ± 18.3

ND

ND

ND

ND

ND

382.2 ± 46.5

ND

ND

RC

AH, IC, RC and VH indicates aqueous humor, iris ciliary body, retina choroid and vitreous humor, respectively.

ND

50

FN 2

ND

50

NB 2

ND

23.9 ± 5.5

17.8 ± 1.5

41.72 ± 2.4

28.1 ± 8.2

100.6 ± 17.9

AH

Sclera

170.2 ± 28.9

146.1 ± 20.8

146.1 ± 20.8

66.4 ± 14.4

624.7 ± 75.3

232.1 ± 33.5

232.1 ± 33.5

232.1 ± 33.5

416.2 ± 42.4

2691.3 ± 923.4

NT levels in ocular tissues (ng/g or ng/mL)

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

VH

- NT, NB, NBG, FN and FNG- represents natamycin, natamycin bilosomes, natamycin bilosome in situ gel formulation, natamycin transfersomes and
natamycin transfersomes in situ gel formulation, respectively.

-

376.3 ± 35.2

50

FNG 2

6

238.1 ± 10.2

50

NBG 2

539.8 ± 106.0

50

FN 2

2

333.6 ± 59.4

50

NB 2

Cornea
4390.4 ± 894.2

(h)

point

2500

(µg)

Time

Control

Formulations

Dose

and FNG 3 formulations (mean ± SEM; n=4).

Table 2.5: The amount of natamycin in the ocular tissues of rabbits at the end of 2h and 6h post-topical administration with control, NB 2, FN 2, NBG 2
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corresponding in situ gel formulation group (p<0.05); ¥-significantly from any formulations group (p<0.05).

ND-not detected. *-significantly different from control (p<0.05); ¶- significantly different from NBG 2 group (p<0.05); ǂ-significantly different from

2), transfersomes (FN 2) and transfersomes in situ gel formulations, at A) 2h and B) 6h time point (mean ± SEM; n=4). *- significantly different at p<0.05.

Fig. 2.6: Mean dose normalized natamycin levels in rabbit ocular tissues from control, optimized natamycin bilosomes (NB 2), bilosomes in situ gel (NBG

NB’s and FN’s across the cornea (p<0.05) (Fig. 2.6A). These results support the findings from
corneal transport studies and could be attributed to the intercalation of bilosomes or transfersomes
with corneal lipids, and their amphiphilic nature, due to the presence of bile salt (ST) or edge
activator (T), driving them to hydrophilic AH (37,67). In contrast, the lipophilic character might
have led the drug, in the cul-de-sac from control suspension (higher amount), to partition into
corneal epithelial cells resulting in high corneal drug levels, however, the poor aqueous solubility
could have limited the penetration through hydrophilic stroma layer in cornea leading to low dose
normalized AH drug concentration. Unlike seen in the cornea, sclera is 10-fold more permeable to
hydrophilic drugs, but it still is impervious to lipophilic molecules (68,69). Thus, the actual amount
of NT in rabbit sclera from control group treated with 50-fold high drug dose was
disproportionately higher by ~6-7 and ~10-12 fold higher over that noted in NB 2, FN 2, NBG 2
and FNG 3 group, respectively, confirming the limited scleral permeation of NT from marketed
suspension (Table 2.5). The significantly higher mean dose normalized NT level in sclera of
rabbits treated with NB 2, FN 2, NBG 2 and FNG 3 formulations, compared to that noticed in the
control group, exemplifies the ability of bilosomes and transfersomes as the potential vehicles to
reduce the scleral barrier characteristics (p<0.05) (Fig. 2.6A). The amount of NT in the IC of
rabbits from all the treatment groups could be attributed to the permeation of drug into the ciliary
body through cornea-scleral limbus junction (29,30) (Table 2.5). The mean dose normalized IC
NT levels were significantly higher in the rabbits treated with NB 2, FN 2, NBG 2 and FNG 3
formulations, compared to that treated with control suspension, which could be attributed to the
transcytosis/endocytosis of these advanced vesicles, through corneal/scleral epithelial cells into
the IC (p<0.05) (Fig. 2.6A) (37,58). As expected, the mean dose normalized drug levels in cornea,
AH, IC and sclera of rabbits administered with NB 2 and FN 2 formulation were significantly
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higher compared to that treated with their corresponding in situ gel systems which could be due to
the slow release of bilosomes and/or transferosomes from the in situ hydrogel matrix (44,47)
(p<0.05) (Fig. 2.6A). The drug levels in the RC and the VH of rabbits from all the treatment groups,
except FN 2 group, were below the detection limit (Table 2.5 & Fig. 2.6). Interestingly, the mean
dose normalized drug levels in IC, sclera and RC of the rabbits treated with FN 2 formulation were
significantly different from that observed in the rabbits in any other groups which could be
attributed to the flexibility of the transfersomes, imparted by the edge activator (TPGS) that helps
distribute them into scleral surface and thereby, diffuse into RC (42,43).
At the end of 6h, no detectable drug levels were noticed in any of the ocular tissues, except
sclera, in the rabbits treated with NB 2 and FN 2 indicating the clearance of the formulation from
the precorneal space (Table 2.5 & Fig. 2.6B). Surprisingly, the cornea, the IC and the sclera of
rabbits from the control group showed some drug levels that could be attributed to depo formation
of drug in the cornea and sclera (Fig. 2.6B). The undetectable drug levels in the AH, the RC and
the VH in these rabbits, however, confirmed no or low drug in the cul-de-sac and poor
transcorneal/transscleral penetration of NT (Fig. 2.6B). These results agree with a study which
reported poor NT levels (< 0.8 µg/mL) in the rabbit tear at 5h post topical administration of
marketed suspension (47). In contrast, significantly higher mean dose normalized drug levels in
all the ocular tissues, except VH, in the rabbits topically administered with NBG 2 and FNG 3
formulations confirmed improved pre-corneal residence time of the in situ hydrogel of NT
bilosomes and transfersomes (Fig. 2.6B). As reported earlier, in situ hydrogels bond with
glycoprotein moieties of the epithelial cells through hydrophobic interactions/van der Waals
forces/ionic/hydrogen bonding and facilitates higher mucoadhesion with the biological
membranes ensuring longer residence time (70). These results confirmed the ability of ion-
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sensitive in situ hydrogels of these advanced vesicles, bilosomes and transfersomes, as potential
platforms for improved and prolong ocular drug delivery.
2.3.9. Stability Studies
Table 2.6: Physical stability of optimized natamycin bilosomes and bilosome in situ gel formulations stored at
4°C and 25°C for 60 days (mean ± SD; n=3).
Formulation

Stored

Time

at

(days)

PS (nm)

ZP (mv)

PDI

% EE

Drug
content (%)

235.0 ± 5.3

-47.0 ± 1.6

0.20 ± 0.01

93.8 ± 4.3

99.2 ± 2.0

30

239.3 ± 4.4

-44.6 ± 3.9

0.21 ± 0.01

91.5 ± 1.2

98.4 ± 1.0

60

243.6 ± 5.9

-45.7 ± 2.0

0.21 ± 0.01

91.4 ± 4.6

98.5 ± 1.3

30

240.7 ± 3.7

-44.6 ± 3.2

0.21 ± 0.02

92.4 ± 2.2

98.4 ± 1.2

60

264.2 ± 10.9*

-44.2 ± 4.7

0.28 ± 0.04*

81.9 ± 1.9*

97.9 ± 2.0

234.3 ± 6.1

-48.0 ± 1.5

0.22 ± 0.07

90.5 ± 1.2

98.9 ± 1.7

Initial

4 °C
NB 2

25°C

Initial
30

236.7 ± 6.9

-46.8 ± 0.4

0.21 ± 0.02

90.5 ± 0.3

98.4 ± 1.5

60

244.4 ± 8.4

-46.7 ± 0.9

0.22 ± 0.01

90.4 ± 1.2

98.3 ± 1.9

30

240.4 ± 3.4

-47.5 ± 4.2

0.22 ± 0.01

89.7 ± 2.3

98.0 ± 1.9

245.4 ± 10.4

-46.7 ± 6.2

0.29 ± 0.16

81.9 ± 1.2

97.9 ± 0.5

4 °C
NBG 2

25°C
0

- NB, NBG, PS, ZP, PDI and % EE represents natamycin bilosomes, natamycin bilosome in situ gel
formulation, particle size, zeta potential, polydispersity index and % entrapment efficiency respectively.
-*- indicates significant difference (p<0.05) between the NB 2 or NBG 2 at 25 oC for 60 days and fresh NB 2 or
NBG 2 at initial conditions (day 0 at room temperature).

The physical stability of the optimized formulations at 4°C and 25°C are specified in Table 2.6 and
Table 2.7. The PS, PDI, ZP and % EE of NB 2 and FN 2 formulations stored at 25°C were not
statistically different for 30 days but changed significantly by 60 days, with respect to those
observed initially (p<0.05) (Table 2.6 and Table 2.7). This could be due to the aggregation of these
vesicles with the leakage of drug. Surprisingly, the physicochemical properties of the NBG 2 and
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FNG 3 formulations did not differ upon storage at 25°C for 60 days which could be attributed to
the viscosity limited migration and aggregation of bilosomes and/or transfersomes (Table 2.6 and
Table 2.7). No variations in the PS, PDI, ZP and % EE of all the optimized formulations stored at
4°C for 60 days suggests that these preparations can be stored at refrigerated conditions (4°C)
(Table 2.6 and Table 2.7).
Table 2.7: Physical stability of optimized natamycin transfersomes and transfersomes in situ gel formulations
stored at 4°C and 25°C for 60 days (mean ± SD; n=3).
Formulation

Stored
at

Time
(days)

PS (nm)

ZP (mv)

PDI

% EE

Drug
content (%)

145.3 ± 2.9

-20.0 ± 1.5

0.20 ± 0.01

84.8 ± 4.8

95.2 ± 1.6

30

146.2 ± 3.4

-19.4 ± 3.9

0.23 ± 0.02

82.4 ± 1.6

97.3 ± 2.0

60

148.4 ± 4.2

-18.6 ± 1.3

0.22 ± 0.02

80.4 ± 3.6

94.5 ± 3.3

30

149.0 ± 3.7

-16.4 ± 2.4

0.25 ± 0.01

83.1 ± 3.2

96.4 ± 2.1

60

164.5 ± 10.9*

-12.2 ± 1.7* 0.38 ± 0.02*

81.9 ± 1.9*

97.9 ± 2.0

-18.1 ± 3.5

0.22 ± 0.01

87.5 ± 3.2

98.9 ± 1.7

Initial

4 °C
FN 2

25°C

148.9 ± 2.1

Initial
30

149.7 ± 2.3

-17.8 ± 1.4

0.21 ± 0.01

86.5 ± 1.3

97.1 ± 2.5

60

150.2 ± 4.4

-16.7 ± 2.4

0.27 ± 0.07

86.4 ± 2.2

98.1 ± 3.1

30

151.4 ± 4.1

-17.5 ± 2.2

0.25 ± 0.01

84.3 ± 3.7

96.2 ± 3.9

60

157.2 ± 9.3

-16.7 ± 6.2

0.29 ± 0.11

82.9 ± 4.2

98.1 ± 6.5

4 °C
FNG 3

5 °C

- FN, FNG, PS, ZP, PDI and % EE represents natamycin transfersomes, natamycin transfersomes in situ
gel formulation, particle size, zeta potential, polydispersity index and % entrapment efficiency respectively.
- *- indicates significant difference (p<0.05) between the FN 2 or FNG 3 at 25 oC for 60 days and fresh FN
2 or FNG 3 at initial conditions (day 0 at room temperature).

2.4. Conclusion
NT bilosomes (NB), corresponding in situ gel systems, NT transfersomes and corresponding in
situ gel systems were successfully fabricated and evaluated. The NB and FN formulation with
equimolar ratio of vesicular components and low amount of bile salt (ST) or edge activator (T)
resulted in uniformly distributed small size vesicles with higher drug % EE. The optimized NB
39

and FN loaded in situ gel (NBG and FNG) systems with 0.3 % w/v gellan gum rapidly transformed
into hydrogel in the STF, which displayed good viscoelastic and adhesive properties. The
cytotoxicity and corneal histology evaluations confirmed compatibility and safety of the bilosomes
formulations on ocular tissues. These studies also revealed that the transfersomes prepared with
0.45 % w/v nonionic surfactants (NS) were safe and compatible for ocular drug delivery but, the
transfersomes obtained with 0.8 % w/v NC induced corneal toxicity causing damage to the
structure of the cornea. The in vitro corneal transport studies confirmed the superior permeability
characteristics of NT from the optimized bilosomes and transfersomes (0.45% w/v NS)
formulations, over control suspension. Furthermore, considerably higher mean dose normalized
drug levels in the ocular tissues from NBG and FNG formulations for 6h, compared to that from
the control suspension, demonstrated the effectiveness of ion-sensitive in situ hydrogels of
bilosomes and transfersomes as the potential carrier systems for the improved and prolonged
topical ocular drug delivery. Nevertheless, the ocular distribution studies of NT from NBs and FNs
with higher drug loads is necessary to confirm the efficiency of these systems as suitable vehicle
for enhanced ocular drug delivery platforms.

40

CHAPTER 3
EFFLUX PROTEINS ON THE BLOOD OCULAR BARRIERS REGULATE OCULAR
DELIVERY OF CHEMOTHERAPEUTIC AGENTS: IMPACT OF SPECIFIC INHIBITORS

3.1. Introduction
The delivery of therapeutics into the deeper ocular tissues via the systemic route remains a
challenge due to the presence of complex blood ocular barriers (BOB). The BOB comprises of the
blood-aqueous barrier (BAB), formed by the epithelial cells of the iris-ciliary bodies, and the
blood-retinal barrier (BRB), made up of the endothelial cells of the retinal blood vessels and the
retinal pigmented epithelium (RPE) (3,4,71-73). The tight-junction proteins and the efflux proteins
present in the BAB and BRB protect the anterior and posterior segment ocular tissues by
preventing the paracellular and/or transcellular transportation of endobiotics and xenobiotics
(3,4,74,75).
In the recent past, numerous researchers have investigated the impact of efflux transporters
on the permeability of hydrophobic anticancer and other drugs across various blood-organ barriers
(71-73). In this regard, the most common efflux proteins are P-glycoprotein (P-gp) and multidrug
resistance protein (Mrp), major efflux proteins belonging to the ATP-binding cassette (ABC)
transporters sub-family. These proteins are widely expressed in many vital organs such as the
brain, liver, lung and kidney, protecting them through the efflux of chemical and biological toxic
substances. The broad substrate specificity of these efflux proteins leads to a severe reduction in
the blood to organ penetration of chemotherapeutic agents (76-79).
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Several investigators have reported the expression of P-gp and Mrp1 or Mrp2 on the ciliary
epithelial cells in the BAB, and on the endothelial cells of the retinal blood vessels and the RPE in
the BRB, in humans and in various animal models (80-84). However, the specific impact of Pgp/Mrp1 in the blood-organ penetration of lipophilic drugs remains uncertain due to the presence
of multiple influx and efflux transporters in the blood-organ membrane barriers (80,85). The coexistence of several influx transporters, like organic cation/carnitine transporters (Oct), organic
anionic transporters (Oat), organic anionic transporter polypeptides (Oatp) and multidrug
resistance associated efflux proteins in the BOB confounds delineation of the contribution of P-gp
and Mrp1 in hindering the blood-ocular transport of drugs (85-87).
The application of multidrug resistance Mdr1a gene, responsible for P-gp expression, and
Mrp1 gene knock-out (KO) mice, and recently rat, models have gained importance in delineating
the P-gp and/or Mrp1 mediated efflux, and its effect on pharmacokinetics of substrates drugs
(88,89). Numerous reports have discussed the use of transgenic mice models lacking the Mdr1a
gene (P-gp KO) or Mrp1 gene as a powerful tool in unlocking the complexity and the role of efflux
proteins on the penetration of anticancer drugs across the blood brain barrier (BBB) (88,89). The
utilization of Mdr1a gene and Mrp1 gene KO mice and/or rats, to determine the impact of efflux
proteins in the BOB, however, has remained largely unexplored.
Several investigations reported the possibility of inhibiting P-gp and Mrp1 activity to
enhance penetration of substrate molecules into the target organs (90,91). Drugs like verapamil,
quinidine, cyclosporine etc., emerged as the first-generation P-gp inhibitors, modulating efflux
activity at the blood-organ interface (92,93). Nonetheless, the toxic and antagonistic effects
associated with their pharmacological activity and their ability to modulate the kinetics of substrate
drugs, limited their use as specific inhibitors (94,95). Interestingly, the second-generation P-gp
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inhibitors with diminished pharmacological activities were more potent and compatible in
reducing the barrier characteristics (90,95,96). The third-generation P-gp inhibitors, like elacridar
(EQ) and tariquidar (TQ), were developed with no pharmacological activity and with higher
affinity to P-gp (at nanomolar concentrations) (90,97,98). EQ and TQ alleviate breast cancer
resistance protein (BCRP) mediated efflux transport of the substrate molecules (97,98). Both EQ
and TQ have been extensively explored for modulating the P-gp transporter at the blood brain
barrier (BBB) thereby, improving the blood to brain penetration of substrate anticancer molecules
(76,97-99). Similarly, MK 571 (MK) and probenecid (PB) were exclusively investigated as potent
Mrp1 inhibitors (100,101). Beside modulating the Mrp1 activity, PB also inhibits the activity of
several other transporters such as Mrp 2-5, Oat, Oct, Oatp etc. (102).
Inhibition of P-gp, but not Mrp1 efflux protein, in the BOB has been studied by several
investigators. The effect of either EQ or TQ on the BRB has been investigated on humans, rabbits
and in vitro cell models, but not in rats (103-105). Previously, the contribution of topically
administered first-generation P-gp inhibitors in improving the blood-ocular penetration of
systemically and intravitreally administered substrates has been successfully investigated in New
Zealand albino rabbits (106,107). However, the effectiveness of the third-generation P-gp
inhibitors (EQ and TQ) and Mrp1 inhibitors (MK and PR) in regulating the activity of the
respective efflux proteins in the BOB in Sprague-Dawley (SD) rats, has not been investigated till
date.
In view of this, the current study, for the first time, aimed to examine 1) the impact of Pgp and Mrp1 barrier properties by comparing the transport of substrate anticancer drugs, paclitaxel
(PTX) and methotrexate (MTX), across the BOB of Mdr1a and Mrp1 KO and wild type (WT) rats
and, 2) the impact of third-generation P-gp inhibitors and Mrp1 inhibitors on the blood-ocular
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transport of these substrate anticancer drugs. Earlier literature reports demonstrated that the bloodbrain transport of PTX was restricted by P-gp and that the transmembrane penetration of MTX
was influenced by Mrp1 activity (88,89,108). Hence, these substrate anticancer drugs were
selected for the present study. Electroretinography (ERG) studies were undertaken to evaluate the
effect of the substrate/inhibitors on the functional activity of the retinal cells.
3.2. Materials and Methods
3.2.1. Animals.
Six to eight-week-old male WT, Mdr1a gene KO and Mrp1 gene KO Sprague-Dawley (SD) rats
were purchased from Horizon Discovery (Saint Louis, MO). The animals had free access to food
and water. All animal experiments were performed according to the approved protocols of the
University of Mississippi Institutional Animal Care and Use committee, the University of
Tennessee Health Science Center Institutional Animal Care and Use committee and the
Association for Research in Vision and Ophthalmology statement for the Use of Animals in
Ophthalmic and Vision Research.
3.2.2. Chemical Reagents
PTX, MTX, Cremophor EL ® and glycofurol was procured from Sigma Aldrich (St. Louis, MO).
EQ, TQ, MK and PR were acquired from Alfa Aesar (Haverhill, MA). Propylene glycol (PG) (1,2Propanediol), Polyethylene glycol 400 (PEG-400), Polyethylene glycol 300 (PEG-300), Dimethyl
Sulfoxide (DMSO) were purchased from Fisher Scientiﬁc (St. Louis, MO). All other high purity
chemicals and HPLC grade solvents were also obtained from Fisher Scientific (St. Louis, MO).
3.2.3. P-gp protein expression by western blotting
Western blot was performed to understand the expression of P-gp in the BAB and BRB of the WT
and P-gp KO SD rats. The WT and P-gp KO rats were euthanized by injecting an excess dose of
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ketamine and xylazine combination through the I.P. route (n=6). The eyes were enucleated
immediately and the ocular tissue (IC and RC) samples were collected. The tissues were harvested,
and tissue lysates were prepared using 2X lysis buffer (Cell Signaling Technology, USA). Protein
concentrations in the tissue lysates were estimated by Bradford assay (Bio-Rad USA). Equal
amounts (20 µg) of proteins, from the various tissue lysates, were loaded into the wells of 10%
SDS-PAGE mini-gels (Bio-Rad, USA), electrophoresed and the proteins were then transferred to
nylon membranes (Cell Signaling Technology, USA) as per the western blot protocol. Membranes
were then blocked in 5% non-fat dried milk in 1X TBST [20 mM Tris–HCl (pH 7.5), 137 mM
NaCl and 0.1% (v ⁄ v) Tween 20] for 1h at room temperature. Blots were probed overnight with
primary antibody MDR1/ABCB1 (Cat # 13978 Cell Signaling Technology) following the
manufacturers protocol. The membranes were washed with 1X TBST and probed with anti-rabbit
secondary antibody conjugated to HRP (Cat # 7074 Cell Signaling Technology) for 1 hr. For equal
loading, samples were probed with beta actin antibody (Cell Signaling Technology, USA). The
blots were developed with signal flame enhanced chemiluminescence (ECL) TM kit (Cell
Signaling Technology, USA). The images were captured, processed and analyzed on
ChemiDoCTM MP imaging system (Bio-Rad, USA). ImageJ was used to compute the area of the
protein band in the blot. Further, relative P-gp protein intensity was calculated from the ratio of Pgp band area and the corresponding β-actin band area.
3.2.4. Preparation and evaluation of substrate and inhibitor intravenous solutions
PTX intravenous solution (3 mg/mL) was prepared by dissolving an appropriate quantity in a
mixture of ethanol (30 %v/v) and cremophor EL (30 % v/v) and final volume was adjusted with
saline (40 % v/v). MTX solution (8 mg/mL) was obtained by dissolving accurately weighed
amount drug in 0.1N NAOH (20 % v/v), pH adjusted to 7.0 with 0.1N HCl (5 % v/v) and final
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volume was made up with water for injection (75 % v/v). EQ solution (10 mg/mL), for intravenous
administration, was obtained by dissolving an accurately weighed amount of EQ in DMSO (5 %
v/v) and then the final volume was made up with glycofurol (5% v/v), PEG 300 (20% v/v), ethanol
(30% v/v) and saline (40 % v/v). A clear solution of 2.5 mg/mL of TQ was prepared by dissolving
an accurately weighed quantity of TQ in DMSO (5% v/v), glycofurol (10% v/v) PEG 400 (30%
v/v), propylene glycol (25% v/v), and the required volume adjusted by the addition of saline. 2.5
mg/mL of MK intravenous solution was prepared by dissolving accurately weighed amount in
DMSO (5 % v/v), glycofurol (10% v/v), ethanol (20 % v/v), PG (30 % v/v) and final volume was
made up with saline (35 % v/v). PB intravenous solution (25 mg/mL) was formulated by dissolving
appropriate amount of PB in DMSO (5 % v/v), 1N NAOH (20% v/v), ethanol (10 % v/v), PG (25
% v/v) and saline (40% v/v) was added to make up to the required volume. All these intravenous
solutions were tested for pH, assay, precipitation in phosphate buffered saline (pH 7.4), stability
at room temperature and for loss during filtration across 0.22µm nylon filter (Millipore, USA).
3.2.5. Electroretinography
The evaluation of substrate (PTX or MTX) or inhibitor (EQ/TQ/MK/PR) incompatibility with the
retinal tissues was investigated by employing electroretinography (ERG) recordings. The analysis
was performed on WT (n=33), P-gp KO (n=12) and Mrp1 KO (n=6) SD rats from the same cohort
utilized in ocular distribution studies, as per the standard protocols.
Substrates only: WT and P-gp KO rats, 12 of each, were intravenously administered 1 mg/kg or 3
mg/kg of PTX and the ERG recording was collected before administration as well as at the end of
2h and 24h (n=3 of each WT and P-gp KO rats/dose/time point) post-drug administration. Three
of each WT and Mrp1 KO rats were administered 8 mg/kg of MTX while another three of each
WT and Mrp1 KO rats were administered 4 mg/kg of MTX. The ERG recording was collected
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before the administration of MTX as well as at the end of 2 h, post-drug administration. Since,
significant changes in ERG patterns were noticed at end of 2h post 8 mg/kg dose treatment,
suggesting the retinal toxicity, no ERG measurements were recorded for 24h.
Inhibitors only: Fifteen WT rats were divided into 5 groups with 3 rats in each group (n=3). Each
study group received only one treatment of intravenous EQ (15 mg/kg) or TQ (15 mg/kg) or TQ
(5 mg/kg) or MK (5 mg/kg) or PR (25 mg/kg). The ERG recordings were measured before and 2h
after inhibitor administration.
Briefly, dark-adapted rats (overnight prior to commencement) were anesthetized with an
I.P. injection of ketamine and xylazine combination. Gold ring electrodes of 2-3 mm diameter
(Roland Consult, Stasche & Finger GmbH), were positioned on both corneas after anesthetizing
them with topical 0.5% proparacaine hydrochloride followed by topical application of 1%
tropicamide for pupil dilation. The stainless-steel surgical needles were inserted subcutaneously
into the forehead and back leg to serve as reference and ground electrodes respectively. The darkadapted ERG responses were recorded from both the eyes simultaneously, exposing them to
flashes of various intensities (from −4.0 Log units to 2.88 Log units) delivered by a Ganzfeld light
source. The amplitudes of a- wave (relevant to photoreceptor functioning by light accommodation)
and b-wave (relevant to bipolar and/or Müller cell functioning) of WT, P-gp KO and Mrp1KO rats
obtained before dosing were considered as baseline to compare and find the differences in the
amplitudes of a- and b- waves recorded by the end of 2 h and/or 1 day after dosing. The deviations
in the intensities of the amplitudes were reported as percentage changes of amplitude.
3.2.6. Ocular distribution
The first objective was to estimate the impact of P-gp and Mrp1 on the ocular penetration of PTX
and MTX, respectively. Ocular distribution studies were thus undertaken in WT, P-gp KO and
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Mrp1 KO rats. Since there was no indication in the literature that the expression of the transporters
on the ocular tissues was gender dependent, male SD rats only were selected for the study. A total
of 96 rats were used in these studies (48 WT, 24 P-gp KO, and 24 Mrp1 KO). Twelve of the WT
and 12 of the P-gp KO rats were administered 1 mg/kg PTX, while the other 24 (12 WT and 12 Pgp KO) were injected 3 mg/kg dose, through the tail vein. Similarly, twelve of each WT and Mrp1
KO rats were administered 4 mg/kg MTX, while the other 24 (12 WT and 12 Mrp1 KO) were
injected 8 mg/kg dose, through the tail vein. At the end of 60 and 120 min, post dosing, WT and
P-gp KO or Mrp1 KO rats from each group (n=6 at each time point) were anesthetized with an
intraperitoneal (I.P.) administration of a combination of ketamine (35 mg/kg) and xylazine (3.5
mg/kg). Blood was collected via cardiac puncture. The animals were then euthanized using an
excess combination dose of ketamine and xylazine through the I.P. route and the eyes were
enucleated immediately. Aqueous humor (AH) and vitreous humor (VH) were collected from both
eyes of each rat and was pooled. The blood samples collected were immediately centrifuged at
10,000 rpm for 5 min and the plasma was separated. Plasma, AH and VH samples were stored at
-80 OC until analysis.
The second objective was to estimate the ability of P-gp inhibitors (EQ and TQ) and Mrp1
inhibitors (MK and PR) to modify the P-gp and Mrp1 activity in the BOB, as evidenced by changes
in the blood-ocular penetration of PTX and MTX. Ocular distribution studies were carried out in
WT SD rats. The rats were placed in 12 treatment groups (n=6), so that each group receive only
one treatment: PTX (1 mg/kg) + EQ (5 mg/kg); PTX (1 mg/kg) + EQ (15 mg/kg); PTX (1 mg/kg)
+ TQ (2.5 mg/kg); PTX (1 mg/kg) + TQ (5 mg/kg); PTX (3 mg/kg) + EQ (5 mg/kg); PTX (3
mg/kg) + EQ (15 mg/kg); PTX (3 mg/kg) + TQ (2.5 mg/kg); PTX (3 mg/kg) + TQ (5 mg/kg);
MTX (4 mg/kg) + MK (2.5 mg/kg); MTX (4 mg/kg) + MK (5 mg/kg); MTX (4 mg/kg) + PR (15
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mg/kg); and MTX (4 mg/kg) + PR (25 mg/kg), through the tail vein. Animals were injected with
P-gp (EQ or TQ) or Mrp 1 inhibitor (MK or PR) 30 min prior to the PTX or MTX administration.
At the end of 60 min post PTX or MTX dosing, the rats were anesthetized by an intraperitoneal
(I.P.) administration of a combination of ketamine (35 mg/kg) and xylazine (3.5 mg/kg) and the
blood was collected via cardiac puncture. The animals were then euthanized with an excess dose
of ketamine and xylazine combination injection through the I.P. route. Immediately after
euthanization, the eyes were enucleated. Aqueous humor (AH) and vitreous humor (VH) were
collected from both eyes and pooled. The blood samples were processed similarly as mentioned
earlier and plasma was collected. All these tissue samples were kept at -80 oC until further analysis
were performed.
3.2.7. Sample Preparation
To 80 µL plasma, 20 µL AH and 40 µL VH tissue samples, 10 µL, 2.5 µL, and 5 µL, respectively,
of 1 µg/mL docetaxel (DTX) (internal standard for PTX(IS)) or 0.5 µg/mL of phenacetin (IS for
MTX) solution was added. Then ice-cold acetonitrile (2 parts) was added to the samples (1 part)
to extract drug and internal standard from the biological matrices with complete precipitation of
proteins. Furthermore, the samples were vortexed and then centrifuged at 13000 rpm for 15 min
and the clear supernatant solution was collected. The eluents in the supernatant solution (2 μL)
were quantified using the following LC/MS method. The extraction efficiency (EE), limit of
detection (LOD) and linearity in plasma (10-100 ng/mL), AH (0.5-40 ng/mL) and VH (0.5-20
ng/mL) was assessed.
3.2.8. Quantification of PTX and MTX
The quantity of PTX and MTX in the plasma, the AH and the VH samples were determined with
the ACQUITY UPLC® I-Class System (Waters Corporation, Milford, MA, USA) connected to
49

Waters Xevo TQ-S triple quadrupole tandem mass spectrometer with an electrospray ionization
(ESI). Data acquisition and processing were controlled by Waters Xevo TQ-S quantitative analysis
TargetLynx software and MassLynx mass spectrometry software, respectively. Separation of PTX
was achieved on an Acquity UPLCTM Cortecs C18 (2.1x100 mm; 2.7 µm) column with operations
were accomplished using a C18 column (Acquity UPLC® BEH C18 100 mm×2.1 m, 1.7µm
particle size). The mobile phase comprised of water (A) and acetonitrile (B), both containing 0.1
% formic acid, at a flow rate of 0.7 mL/min, which were applied in the following gradient elution:
0 min,55 % A: 45% B, in next 2.5 min to 50% B, and next 0.2 min; to 100 % B, and then to 55%
A for next 2.5 min. Each run was followed by a 3 min wash with 100 % acetonitrile, and an
equilibration period of 1 min. The column temperature was set at 50 °C. Two microliters of sample
was injected into the column and the effluent was directed into the ESI probe (source) operated
using following parameters: source temperature 60°C, desolvation temperature 600°C, capillary
voltage 2.0 kV, cone voltage 30 V, nebulizer pressure-7 bar, desolvation gas flow 1200 L/h N2 and
cone gas flow 150 L/h N2. The collision energies ranging from 20 to 64 eV were optimized, for
individual analytes. Argon served as the collision gas. All the instrument operations were
controlled by MassLynx software (version 4.1, Waters, Milford, MA, USA). Mass spectra of each
sample was acquired in positive mode. The precursor to daughter ions transitions (quantifier ion
to qualifier ions transitions) of PTX (m/z 854.31 → m/z 286.14, 122.08, 195.06) and docetaxel
(DTX) (m/z 808.37 → m/z 527.23, 327.15, 105.06) was monitored in multiple reaction monitoring
(MRM) mode. The compounds were confirmed in each spectrum by the three daughter ions, each
for PTX and DTX.
Similarly, the MTX was also analyzed using the same LC/MS system, column mobile
phase, at a flow rate 0.8 mL/min, with slight changes in gradient elution as following; till 0.2 min,
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98 % A: 2% B, in next 2.5 min to 100% B and maintain for 1 min then to 98% A:2% B, in next 1
min. Each run was followed by a 1 min wash with 100 % acetonitrile, and an equilibration period
of 3 min. The column and sample temperatures were set at 50 °C and 10 °C, respectively. Two
microliters of sample was injected into the column and the effluent was directed into the ESI probe
(source) operated using following parameters: source temperature 60°C, desolvation temperature
600°C, capillary voltage 2.0 kV, cone voltage 10 V, nebulizer pressure-7 bar, desolvation gas flow
1200 L/h N2 and cone gas flow 200 L/h N2. The collision energies ranging from 18 to 34 eV were
optimized, for individual analytes. Mass spectra of each sample was acquired in positive mode.
The precursor to daughter ions transitions (quantifier ion to qualifier ions transitions) of MTX (m/z
455.08 → m/z 308.16, 175.08, 134.08) and phenacetin (PH) (m/z 180.06 → m/z 110.06, 92.90,
65.08) was monitored in multiple reaction monitoring (MRM) mode. The compounds were
confirmed in each spectrum by the three daughter ions, each for MTX and PH.
3.2.9. Data Interpretation
The variations in the plasma concentration of substrate drug (PTX or MTX) could be attributed to
the differences in their AH and the VH levels, which could confound the impact of P-gp or Mrp1
on the permeation process. Hence, ocular tissue-to-plasma ratio of substrate drug concentration is
a more important parameter to determine the impact of P-gp or Mrp1 activity and inhibition in the
BOB.
Thus, drug (PTX or MTX) distribution into the AH and VH from plasma was calculated
according to equations 1 & 2 respectively,
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Where, DAH and DVH represents the distribution ratios delineating the penetration of PTX or MTX
from plasma into AH and VH, respectively.
3.2.10. Statistical analysis
The data obtained from ocular distribution and ERG studies were subjected to one-way analysis
of variance (ANOVA) and Tukey’s post hoc HSD (GraphPad Software, San Diego California,
USA), to estimate the statistical signiﬁcance. The p < 0.05 were considered statistically significant.
3.3. Results and discussions
All intravenous solutions were clear with pH of 6.7 -7.0 and showed an assay of 94.8-103.0%
(Table 3.1). No significant loss of drug (< 1 %) was noted during filter validation (passing these
solutions through 0.22 µm nylon filter). Moreover, no precipitation was seen after introducing
these solutions into phosphate buffer saline (pH 7.4), ruling out the possibility of precipitation at
the injection site (Table 3.1).
Table 3.1: Evaluation of formulations containing P-gp and Mrp1 substrates and
inhibitors.
Evaluation
parameters

Formulations
PTX

EQ

TQ

MTX

PB

MK

% Assay

102.31

103.03

97.88

101.31

95.49

94.80

pH

6.7

6.7-6.8

6.7-6.8

6.8-7

6.8-7

6.8

0.34

0.44

0.36

0.43

0.51

0.53

Clear

Clear

Clear

Clear

Clear

Clear

No

No

No

No

No

No

30 days

30 days

7 days

30 days

7 days

7 days

Loss on
Filtration
(%)
Appearance
On-site
precipitation
Stability @
RT
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All these formulations were stored at room temperature for 1-4 weeks and were found to be stable
with ≤ 2% change in the assay during this period (Table 3.1). These intravenous solutions were
prepared as mentioned in earlier literature reports, with slight modifications (103-105,108). The
excipient concentrations utilized in the formulations were within the limits noted in the inactive
ingredients (IIG) database of US Food and Drug Administration (US-FDA) and/or below reported
intravenous LD50 values in rats, to ensure safety and biocompatibility of these parenteral solutions
(109,110).
The LC/MS method adopted for the analysis of PTX and MTX was sensitive with a limit of
detection (LOD) of 0.1 ng/mL, and a limit of quantitation (LOQ) of 0.5 ng/mL in the ocular tissues
and was linear over the range of concentrations tested with r2 values of 0.993, 0.990 and 0.994 in
plasma, AH and VH, respectively. >85 % of PTX and ~92 % of MTX were extracted from all
tissues by protein precipitation technique using ice cold acetonitrile. The bioanalytical method was

Fig. 3.1: A) Western-blot displaying the P-gp protein and β-actin bands in the IC and RC samples obtained from
WT and P-gp KO SD rats. B) The relative P-gp protein intensity was determined from the ratio of area obtained
from P-gp protein band and β-actin band using ImageJ.
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specific to PTX and/or MTX, specific IS’s as well, without any interference. The % recovery of
these substrate drugs from the samples stored at 40 OC and freshly obtained samples were 93.3 %
and 91.3%, respectively, suggesting low or no drug loss during the storage of the samples.
3.3.1. P-gp protein expression in ocular tissues
Literature reports describe the utility of the western blotting, reverse transcription-polymerase
chain reaction (RT-PCR) and immunohistochemistry techniques in determining the P-gp protein
expression in the ocular tissues (111). In the current study, the western blot results portrayed a
protein band with MW ~170 kDa in the IC and RC samples obtained from the WT, confirming the
existence of the P-gp protein in the BAB and the BRB, respectively (Fig. 3.1A). The higher relative
P-gp protein intensity in the IC compared to that in the RC demonstrated higher P-gp expression
in the IC than in the RC, suggesting greater MDR 1a efflux activity in the BAB over that in the
BRB (Fig. 3.1B). A few literature reports also demonstrated the variations in the P-gp mediated
efflux of substrates at the BAB and the BRB, in rat models, confirming the differential expression
of P-gp in the BAB and the BRB (112, 113). In contrast, no band at 170 kDa MW mark in the IC
and RC tissues collected from P-gp KO rats confirmed the absence of P-gp expression in their
BAB and the BRB. Thus, these results suggest the applicability of P-gp KO rats as a suitable model
to delineate impact of P-gp mediated efflux of anticancer drugs in the BOB.
3.3.2. Electroretinography
Electroretinography (ERG) was performed to understand substrate-inhibitors interactions with the
retina thereby affecting the functioning of photoreceptors cells and inner retinal cells. The ERG
measures the functioning of photoreceptor cells and bipolar/Müller cells as a-wave and b-wave,
respectively. Changes in the a-wave recording suggest light or chemical induced alterations in the
functioning of photoreceptors cells in the outer segment of the retina, while the variations in the
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b-wave recordings suggest damage to the inner retina (114-116). Hence, the % change in the
amplitude of a- and b-wave were examined to understand the cytocompatibility of substrate and/or
inhibitor interactions with retina of WT, P-gp KO and Mrp1 KO SD rats.
The percentage changes of a- and b- wave amplitudes obtained from the ERG studies in WT and

Fig. 3.2: Electroretinography results depicting the % change from the baseline in the amplitude of a- and bwave recorded A) at 2h and 1day post PTX (two doses) in WT and P-gp KO rats, and B) at 2h post
administration with MTX (two doses) in WT and Mrp1 KO rats, and C) at 2h post P-gp (EQ and TQ) or Mrp1
inhibitor (MK and PR) in WT rats (mean ± SEM, n=3). * - significantly different at p<0.05.

P-gp KO rats, pre- and post-dosing of PTX (two doses), is presented in Figure 3.2A. The a-wave
amplitude in P-gp KO rats, 2h and 1day post treatment with 3 mg/kg of PTX, changed significantly
with respect to baseline (p<0.05) (Fig. 3.2A). Similarly, at 1day post treatment with 3 mg/kg PTX,
the b-wave amplitude, in P-gp KO rats, changed significantly from the baseline suggesting the
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damage of inner retinal layer by PTX, at this dose (p<0.05) (Fig. 3.2A). These results verify several
reports which demonstrated PTX induced retinal degeneration, at higher dose (3-6 mg/kg)
(117,118). No change was observed in the a- and b-wave amplitude in both WT and P-gp KO rats
administered with low dose (1 mg/kg) of PTX (Fig. 3.2A), confirming the lack of structural and
functional alterations in the retina.
The WT rats treated with MTX high dose (8 mg/kg) showed a significant % change in the
a-wave amplitude, from the baseline, 2h post treatment, but no change in the b- wave was noticed.
The ERG wave pattern recorded in the Mrp1 KO rats, 2h post MTX treatment, were not different
from the baseline recording. These results suggested that MTX at higher dose could cause a toxic
interaction with retina (Fig. 3.2B). ERG recordings measured in WT and Mrp1 KO rats
administered with low dose (4 mg/kg) of MTX were not statistically different from the baseline
recording and suggested that MTX at low dose (4 mg/kg) is retina compatible (Fig. 3.2B).
All the inhibitors (EQ, TQ, MK and PR) were tested for their retinal compatibility, in WT
rats, and, safe doses were selected for the ocular distribution studies. The % change in the
amplitude of a- and b-wave recordings of all the inhibitors is given Figure 3.2C. Except for TQ 15
mg/kg dose, all other inhibitors, at tested doses, did not show significant % change in the a and b
wave amplitude with respect to the baseline suggesting retinal safety. However, TQ at 15 mg/kg
showed significant % change in the b-wave amplitude from the baseline recording, at 2h post
dosing, suggesting retinal toxicity at this dose. The lower TQ dose was observed to be safe.
3.3.3. Ocular distribution
The substrates and inhibitor doses tested in the present studies were selected from literature
reports which demonstrated the impact of P-gp and Mrp1 activity and inhibition in the BBB of
WT and/or P-gp or Mrp1 KO rats/mice (76,101-105,119,120).
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3.3.3.1.

Impact of P-gp activity and it’s inhibition on the blood-ocular penetration of

PTX
a. Plasma concentration of PTX
PTX concentration determined in the plasma of rats from different treatment groups are
represented in Figure 3.3. A dose related increase in the plasma PTX levels was observed in both
WT and P-gp KO rats (Figure 3.3A). As the administered dose of PTX increased from 1 mg/kg to

Figure 3.3: The plasma concentrations of PTX in the rats from different treatment groups. A) Plasma PTX levels
in WT and P-gp KO rats, at 60 and 120 min post administration with 1 mg/kg or 3 mg/kg dose of PTX. B) Plasma
PTX levels in the WT rats, at 60 min post co-administration with P-gp inhibitors (EQ or TQ) and PTX (1 mg/kg).
α- indicates significant difference at p<0.05, between WT or P-gp KO 1 mg/kg vs WT or P-gp KO 3 mg/kg, at
same time point; *-indicates significant difference at p<0.05, between WT vs P-gp KO, at same dose and time
point (mean ± SEM, n=6).

3 mg/kg, a ~3 – 4-fold increase in the plasma drug concentrations was observed in both WT and
P-gp KO rats, at both the time points (p<0.05) (Fig. 3.3A). The plasma PTX concentration in the
P-gp KO rats was significantly higher compared to the WT rats, at 60 min (both doses) and 120
min (3 mg/kg dose alone) (p<0.05) (Fig. 3.3A). At 120 min post 1 mg/kg administration, the
plasma PTX concentration in the P-gp KO rats were slightly higher over that observed in WT rats
but were not statistically different (Fig. 3.3A). These results corroborate with previous reports
which demonstrated a ~1.5-fold higher plasma PTX levels in the P-gp KO rats, compared to WT
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(88). This is probably due to reduced renal clearance of PTX in the Mdr1a gene KO rats due to the
lack of P-gp expression in the renal cells (88).
At 60 min post PTX (1 mg/kg) administration, the plasma PTX concentration observed in
the WT rats pretreated with P-gp inhibitors (either EQ or TQ, at both doses) were slightly higher,
but not statistically different, from that observed in the WT rats treated with PTX alone (Fig. 3.3B).
This might be due to the partial or incomplete inhibition on P-gp activity, by EQ or TQ (at tested
doses), leading to no significant change in the renal clearance of PTX.
b. Blood-to-AH penetration of PTX
To estimate the penetration of PTX into the AH from the systemic circulation, AH PTX and the
AH to plasma distribution ratio of PTX (DAH), in P-gp KO rats and WT rats in different treatment
groups, were estimated and are illustrated in Figure 3.4.
Dose related drug levels were noticed in the AH of WT and P-gp KO rats, at both doses
and time points (Fig. 3.4A). At the lower dose (1 mg/kg), PTX concentrations were below LOD
in the AH of the WT rats at both time-points (Fig. 3.4A). On the other hand, at the same dose,
significant PTX levels were detected in the AH of P-gp KO rats, at the both time points, but, the
concertation of PTX noted at120 min were below the LOQ (Fig. 3.4A). The penetration or
distribution of PTX from blood into AH was determined as the AH to plasma drug concentration
ratio (DAH). The DAH of PTX in WT rats treated with the low dose was zero for both the timepoints since no drug levels were detected in the AH. The DAH of PTX in the P-gp KO rats injected
with low dose (1 mg/kg) was significantly better compared to that of the WT rats, at 60 min
(p<0.05) (Fig. 3.4B). At the higher dose (3 mg/kg) treatment, the average concentrations of PTX
in the AH obtained in the P-gp KO rats, at 60 min, were ~ 2-fold higher (p<0.05) than that of the
WT rat (Fig. 3.4A). The DAH of PTX in P-gp KO rats were significantly higher than that seen in
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WT rats, at 60 min. Hence at 60 min point, at both the doses, the influence of P-gp on the transport
of PTX across the BAB was clearly evident (p<0.05) (Fig. 3.4A). These findings agree with
previous reports on the expression of P-gp at BAB (3,81). At 120 min, no or low DAH in both WT

Fig. 3.4: The aqueous humor (AH) PTX levels (A & C) and AH to plasma distribution ratio of PTX (DAH) (B
& D) in the P-gp KO rats and/or WT rats in different treatment groups. ND-Not detected; BQ- Below the
LOQ; NC-Not calculated;* - indicates significant difference at p<0.05, between WT or P-gp KO 1 mg/kg vs
WT or P-gp KO 3 mg/kg, at same time point or between WT rats pretreated with low dose of P-gp inhibitors
(EQ or TQ) vs WT rats pretreated with high dose of P-gp inhibitors (EQ or TQ), at 1 mg/kg dose of PTX and
60 min point; α -indicates significant difference at p<0.05, between WT vs P-gp KO, at same dose and time
point; #-significantly different from WT rats treated with PTX (1 mg/kg) alone (p<0.05), ᴪ- significantly
different from all (p<0.05) (mean ± SEM, n=6).

and P-gp KO, compared to that observed at 60 min, suggests the elimination of drug from the
blood and the AH, at both the doses of PTX.
Surprisingly, the DAH of PTX in P-gp KO rats administered with 1 mg/kg dose, at 60 min,
was significantly higher than that observed in P-gp KO rats treated with 3 mg/kg dose (Fig. 3.4B).
This could be possibly due to the damage to the BOB induced by PTX at 3mg/kg dose, as noticed
in the ERG studies. Thus, 1 mg/kg PTX dose was selected to investigate the impact of the P-gp
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activity inhibition on the blood-AH penetration of PTX in the WT rats pretreated with third
generation specific P-gp inhibitors, EQ and TQ.
In the presence of EQ or TQ (at both the doses), the penetration of PTX (1 mg/kg
dose) into the AH from blood in the WT rats were significantly higher (p<0.05) compared to that
in the WT rats not receiving the inhibitors (Fig. 3.4C). The AH levels and DAH of PTX in WT rats
co-administered with P-gp inhibitors and PTX increased with an increase in the EQ or TQ dose
(Fig 3.4C). A 2-fold improvement in the AH PTX levels and DAH of PTX were noticed in WT rats,
pre-administered with high dose of EQ (15 mg/kg) or TQ (5 mg/kg), compared to that seen in the
WT rats administered with low dose of EQ (5 mg/kg) or TQ (2.5 mg/kg) (Fig 3.4C and Fig. 3.4D).
These results indicate enhanced plasma to AH penetration of PTX, suggesting effective
modulation of P-gp in the BAB by the inhibitors (EQ or TQ). The above findings corroborate with
the literature reports which demonstrate the interaction of EQ and TQ with the MDR 1a efflux
transporter function. This modulation of P-gp efflux activity is due to blocking of the
drug/substrate binding site by EQ or because of blocking of both drug binding and ATP binding
sites by TQ, in the P-gp structure (97,122). The AH PTX levels and DAH of PTX in the WT rats
administered with EQ, at low dose (5 mg/kg), were not statistically different from those noted in
the rats pretreated with TQ, at low dose (2.5 mg/kg) (Fig 3.4C and Fig. 3.4D). Similarly, no
statistically significant difference was found between the AH PTX levels and DAH of PTX in the
WT rats treated with 15 mg/kg dose of EQ and WT rats injected with 5 mg/kg of TQ (Fig 3.4C
and Fig. 3.4D). It has been reported that TQ (IC50 ≤ 0.05 µM) has greater affinity for P-gp
compared to EQ (IC50 ≤ 0.1 µM) (97). Hence, even at 2-3-fold lower dose compared to EQ, TQ
produced P-gp inhibitory effects similar to that of EQ and no statistical difference in AH PTX
levels and DAH was noted (Fig 3.4C and Fig. 3.4D).
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The above results confirm that P-gp on the BAB restricts penetration of PTX into the AH from the
blood and that effective inhibition of this P-gp activity improves the penetration of PTX across the
BAB into the AH.
c. Blood-to-VH penetration of PTX
Dose related VH PTX levels were observed in both WT and P-gp KO rats (Fig. 3.5A). In the VH
of WT rats, at 1 mg/kg dose, PTX concentrations were below LOD at both time-points whereas,
significant PTX levels were detected in the VH of P-gp KO rats at the 60-min time-point (Fig.

Fig. 3.5: The vitreous humor (VH) PTX levels (A & C) and VH to plasma distribution ratio of PTX (DVH) (B & D)
in the P-gp KO rats and/or WT rats in different treatment groups. ND-Not detected; NC-Not calculated; BQ- below
the LOQ; * - indicates significant difference at p<0.05, between WT or P-gp KO 1 mg/kg vs WT or P-gp KO 3
mg/kg, at same time point or between WT rats pretreated with low dose of P-gp inhibitors (EQ or TQ) vs WT rats
pretreated with high dose of P-gp inhibitors (EQ or TQ), at 1 mg/kg dose of PTX and 60 min point; α -indicates
significant difference at p<0.05, between WT vs P-gp KO, at same dose and time point; #-significantly different
from WT rats treated with PTX (1 mg/kg) alone (p<0.05) (mean ± SEM, n=6).

3.5B). Hence, the plasma to VH PTX distribution ratio (DVH) in P-gp KO rats receiving the lower
dose, at 60 min, was significantly higher compared to that of the WT rats (p<0.05) (Fig. 3.5B).
61

This demonstrates the superior penetration of PTX from blood to VH through the BRB of subjects
lacking P-gp. Moreover, no PTX levels in the VH of WT rats suggests the influence of P-gp, at
the blood-VH interface, on the penetration of PTX across the BRB. These results are in agreement
with the previous literature reports on the barrier properties of P-gp in the BRB (3,4,80). With the
3 mg/kg dose treatment, the VH PTX concentrations in the WT and P-gp KO rats, were not
statistically different from each other, at any time point. Thus, the DVH of drug in WT and P-gp
KO rats did not show significant difference at both time intervals post 3 mg/kg treatment (Fig.
3.5B). This could be attributed to the retina structural damage induced by PTX, at 3 mg/kg dose,
which was apparent from the ERG studies. Moreover, numerous investigations have reported that
PTX, at high doses (3-6 mg/kg), induce retina degeneration in humans and SD rats (117,118).
Hence, the 1 mg/kg dose and the 60 min time point were selected to investigate the impact of
modulation of P-gp activity, by EQ or TQ, on the penetration of PTX across the BRB.
The WT rats co-administered with high dose of EQ (15 mg/kg) or TQ (5 mg/kg) and PTX
(1 mg/kg) showed greater VH PTX levels over that seen in the WT rats administered with PTX
alone (p<0.05) (Fig. 3.5C). Hence, the VH to plasma PTX distribution ratio (DVH) in WT rats
receiving high dose of EQ and/or TQ were significantly higher compared to that of the WT rats
receiving PTX alone (p<0.05) (Fig. 3.5D). As seen in blood-to-AH penetration of PTX, the VH
levels and DVH of PTX in rats administered with higher dose of EQ or TQ were significantly higher
than that of the rats administered with lower dose of inhibitors, and thus, suggested a dose related
inhibition of P-gp activity (p<0.05) (Fig. 3.5C & Fig. 3.5D). However, at low dose of P-gp
inhibitors, no PTX levels were detected in the VH of rats treated with TQ while the WT rats treated
with EQ showed VH PTX levels, which were below the LOQ (Fig. 3.5C). This could be attributed
to the partial or no inhibition of P-gp activity in the BRB by the EQ and TQ at low doses. These
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results demonstrated effective modulation of P-gp activity in the BRB by EQ and TQ and agreed
with the previous literature reports that demonstrate improved penetration of substrates across the
BRB on modulating P-gp activity (80,105).
3.3.3.2.

Impact of Mrp1 activity and inhibition on the blood-ocular penetration of

MTX
a. Plasma Concentration of MTX
Figure 3.6 delineates the plasma MTX concentrations in the WT rats and Mrp1 KO rats.
The plasma concentration of MTX in both WT and Mrp1 KO rats was increased by ~ 2 - 3.5-folds
with an increase in the administered MTX dose from 4 mg/kg to 8 mg/kg (Fig. 3.6A). At same
dose and time point, the plasma MTX levels in the WT rats were about 1.2-3-fold higher compared
to that seen in Mrp1 KO rats (Fig. 3.6A). Mrp1 efflux protein, situated on the basal side of the
renal proximal tubular cells, promotes the renal reuptake of substrate drugs (102,123). Thus, the
reduced reuptake of MTX in the Mrp1 KO rats resulted in lower plasma concentrations, compared
to WT rats (Fig. 3.6A). The WT rats in the inhibitor treatment group also showed variations in the
plasma MTX levels. At 60 min post-treatment with MTX in the WT rats pretreated with MK (at
any given dose), the plasma concentration of MTX was not statistically different from that
observed in the WT rats injected with MTX alone (4 mg/kg) (Fig. 3.6B). This could be attributed
to the low levels of MK in the renal tubules resulting in no or partial inhibition of Mrp1 activity in
the kidney and, thus, lead to MTX reuptake. The WT rats pre-administered with PR (at both doses)
showed about 1.5 - 2.2-folds higher plasma concentration of MTX compared to that seen in WT
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rats in any other group and Mrp1 KO rats injected with 4 mg/kg MTX (Fig. 3.6). This remarkable
difference in the plasma MTX levels seen in WT rats pretreated with PR (at both doses) could be

Fig. 3.6: The plasma MTX levels A) WT and Mrp1 KO rats treated with 4 mg/kg or 8 mg/kg, at 60 and 120 min,
and B) WT rats co-administered with different doses Mrp1 or PB and MTX. of in different treatment groups. σ indicates significant difference at p<0.05, between WT or Mrp1 KO 8 mg/kg vs WT or Mrp1 KO 4 mg/kg, at same
time point; φ- indicates significant difference at p<0.05, between WT vs Mrp1 KO, at same dose and time point;
∆- indicates significant difference at p<0.05, between MTX (4 mg/kg) and PB (25 mg/kg or15 mg/kg) vs MTX (4
mg/kg) and MK (2.5 mg/kg or 5 mg/kg), WT (4 mg/kg) at 60 min and Mrp1 KO (4 mg/kg), at 60 min (mean ±
SEM, n=6).

attributed to the effectiveness of PR in inhibiting a wide range of Mrp’s, Oat’s, Oatp’s etc (p<0.05)
(102). These results support the previous literature reports which demonstrated PR as a potent
inhibitor of Mrp2, Oat1 and Oat3 transporters, besides Mrp1, situated on the apical cells of
proximal renal tubule and involved in the renal clearance of substrate drugs (102). Hence, the
inhibition of Oat1, Oat3 and Mrp2, by PR, in the kidney resulted in decreased renal clearance of
MTX and thereby increased plasma MTX levels in the WT rats.
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b. Blood-to-AH penetration of MTX
The AH levels and DAH of MTX in WT rats and Mrp1 KO rats, in different treatment groups, are
presented in Figure 3.7. The MTX levels in the AH of WT and Mrp1 KO rats increased,

Fig. 3.7: The aqueous humor (AH) MTX levels (A & C) and AH to plasma distribution ratio of MTX (DAH) (B &
D) in the Mrp1 KO rats and/or WT rats in different treatment groups. * - indicates significant difference at p<0.05,
between WT or Mrp1 KO 8 mg/kg vs WT or Mrp1 KO 4 mg/kg, at same time point; σ-significantly different from
WT (4 m/kg MTX), at 60 min (p<0.05); Ф -significantly different from Mrp1 KO rats treated with MTX alone, at
60 min (4 mg/kg) (p<0.05;α- indicates significant difference at p<0.05, between WT rats co-administered with
MTX and MK or PB (high dose) vs WT rats co-administered with MTX and MK or PB (low dose); #-significantly
different from WT rats treated with MTX (4 mg/kg) alone, at 60 min (p<0.05), ᴪ - significantly different from all
(p<0.05) (mean ± SEM, n=6).

corresponding to the dose administered, at 60 min (both at 4 mg/kg and 8 mg/kg dose) and 120
min (only at 8 mg/kg) (Fig. 3.7A). At the 4 mg/kg dose, the AH MTX levels and the DAH of MTX
in Mrp1 KO rats were about 2-fold higher (p<0.05) compared to that in the WT rats, at the 60 min
time point (Fig. 3.7A and Fig. 3.7B). This suggests Mrp1 mediated efflux activity in the BAB,
consistent with the literature reports that demonstrate Mrp1 expression in the apical membrane of
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the non-pigmented ciliary epithelial cells (124, 125). Hence, in the absence of Mrp1 efflux protein
expression in the KO rats, the AH MTX levels were higher compared to that noted in WT rats, at
60 min post 4 mg/kg dose treatment. At 8 mg/kg dose, the AH concentrations of MTX in WT rats,
at both time points, were not significantly different from that observed in the Mrp1 KO rats which
could be due to the damage to BOB, as seen in the ERG studies (Fig. 3.2C). Thus, the DAH of MTX
estimated in the WT and Mrp1 KO rats, at both time points in 8 mg/kg dose study, were not
statistically different (Fig. 3.7B). The AH MTX levels and the DAH of MTX in WT and Mrp1 KO
rats, at 120 min, was about 2-4-fold lower compared to that noted at 60 min, at same administered
dose, which might be possibly due to the clearance of MTX from plasma and AH. However, at 60
min post 4 mg/kg dose treatment, the higher MTX concentrations in the AH and DAH of MTX in
Mrp1 KO rats, over the WT rats, confirmed the active Mrp1 mediate efflux of the MTX across the
BAB. Hence, this dose and time point was selected to understand the role of the Mrp1 inhibition
on the penetration of MTX across the BAB.
The AH levels and the DAH of MTX estimated in the WT rats co-administered with MTX
(4 mg/kg) and MK (5 mg/kg or 2.5 mg/kg) and/or PR (15 mg/kg or 25 mg/kg) were significantly
higher compared to that seen in WT rats receiving MTX alone (Fig. 3.7C and Fig. 3.7D). This
confirmed effective modulation of Mrp1 activity in the BAB and thereby, improved penetration of
MTX into AH from blood. As the administered dose of the MK or PR ~ doubled, the AH MTX
levels and DAH in the WT rats increased by about 1.5-2.0-fold and 1.2-1.7-fold, respectively, and
suggested an inhibitor dose related modulation of Mrp1 activity at the BAB (Fig. 3.7C).
Penetration of MTX into the AH (DAH) from the systemic circulation, in WT rats pretreated with
low dose of MK (2.5 mg/kg) and PR (15 mg/kg), were similar confirming similar Mrp1 inhibition
by these inhibitors at a 5-6-fold dose difference. The AH MTX levels in WT rats administered
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with PR high dose (25 mg/kg) were significantly higher compared to that seen in WT rats
pretreated with MK high dose (5 mg/kg) (Fig. 3.7C). But, the DAH of MTX in WT rats treated with
MK (5 mg/kg) was significantly higher compared to that observed in rats treated with PR (25
mg/kg) (Fig. 3.7D). This could be attributed to the higher MTX levels in plasma of rats pretreated
with PR (25 mg/kg) compared to that seen in rats treated with MK (5 mg/kg) (Fig. 3.6B). These
results support and corroborate the earlier literature reports which demonstrate effective inhibition
of Mrp1 activity in the BBB and other blood-organ barriers by MK (100,101).
c. Blood-to-VH penetration of MTX
In both WT and Mrp1 KO rats, a dose related VH MTX levels were observed at the 60 min time
point (Fig. 3.8A). In the 4mg/kg dose study, the MTX concentrations in the VH of Mrp1 KO rats

Fig. 3.8: The vitreous humor (VH) MTX levels (A&C) and VH to plasma distribution ratio of MTX (DVH) (B&D)
in the Mrp1 KO rats and/or WT rats in different treatment groups. * - indicates significant difference at p<0.05,
between WT or Mrp1 KO 4 mg/kg vs WT or Mrp1 KO 8 mg/kg, at same time point; σ - indicates significant
difference at p<0.05, between WT vs Mrp1 KO, at same dose and time point; Ф -significantly different from WT
rats treated with MTX (4 mg/kg) alone, at 60 min (p<0.05); φ- significantly different from Mrp1 KO rats treated
with MTX (4 mg/kg) alone, at 60 min; ᴪ - significantly different from all (p<0.05) (mean ± SEM, n=6).
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were significantly higher (p<0.05), at the 60 min time-point, compared to that seen in WT rats
(Fig. 3.8A). Hence, the VH to plasma MTX distribution ratio (DVH) in Mrp1 KO rats, treated with
the lower dose was significantly higher (p<0.05) compared to that of the WT rats, at 60 min (Fig.
3.8B). This suggests that the penetration of MTX across, the BRB, is influenced by Mrp1 efflux

protein activity. These results verify the previous literature reports that demonstrate the expression
of Mrp1 efflux protein on the BRB (78). The MTX concentrations in the VH of the WT and Mrp1
KO rats, at 8 mg/kg dose study, were not statistically different (Fig. 3.8A). Hence, no significant
difference was noticed in the DVH of drug in WT and Mrp1 KO rats at both time intervals post
higher dose treatment (Fig. 3.8B). Reports in the literature demonstrated that MTX induce
reversible optic neuropathies, at higher doses (125). The ERG studies also confirmed that MTX,
at high dose (8 mg/kg) resulted in the damage to the retina architecture and functions. Hence, the
damaged retina could have accommodated MTX in the VH and thus, resulted in similar DVH of
MTX in WT and Mrp1 KO rats.

Considering the remarkable impact of Mrp1 activity at the 60 min time point post 1 mg/kg
MTX dose treatment, this dose and time point was selected to study the effect of Mrp1 inhibition
by MK and PR, on the penetration of MTX across the BRB. Significantly higher (p<0.05) MTX
levels were observed in the VH of rats treated with MTX and Mrp1 inhibitors (MK and PR), over
that seen in the rats administered with MTX alone (4 mg/kg) (Fig. 3.8C). Hence, significantly
higher VH to plasma MTX distribution ratio (DVH) in rats receiving MK or PR (at both doses)
were seen, compared to that observed in the rats dosed with MTX alone (4 mg/kg) (p<0.05) (Fig.
3.8D). The DVH of MTX in WT rats co-administered with MK or PR and MTX were about 2-folds
higher compared to that noted in Mrp1 KO rats (at 4 mg/kg and at 60 min) (Fig 3.8A and Fig.
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3.8D). This can be owed to effective inhibition of Oat3, beside Mrp1, in the BRB by MK and PR.
The Oat3, an influx transporter positioned on the apical membrane of inner BRB blood vessels,
keep the substrate drug in the blood while the Mrp1, an efflux protein located on the basolateral
membrane of the RPE (away from VH), prevent the transportation of substrate drugs across the
outer BRB into the VH (100-102). Thus, effective inhibition of these transporter proteins by MK
and PR allowed greater drug penetration into the VH from blood. These results demonstrate that
the effective modulation of Mrp1 activity in the BRB, by MK and PR, improved the blood-VH
penetration of MTX.
3.4 Conclusion
The over-all results from the comparative ocular distribution studies in WT, P-gp KO and Mrp1
KO rats delineated the influence of P-gp efflux transporter and Mrp1 efflux protein on the bloodocular penetration of PTX and MTX, respectively. A dose related effect of PTX and MTX were
noticed with respect to the impact of P-gp/Mrp1 activity in the BOBs. The effect of P-gp and Mrp1
on the penetration of these anticancer drugs across the BOB were more evident at the lower dose.
The improved distribution of PTX and MTX into the AH and VH from the systemic circulation in
the P-gp KO and Mrp1 KO rats, illustrates the existence and magnitude of the efflux proteins (Pgp and Mrp1) barrier characteristics in the BAB and the BRB. An improvement in the blood ocular
penetration of PTX and MTX, in the WT rats, in the presence of specific P-gp inhibitors (EQ and
TQ) and Mrp1 inhibitors (MK and PR) point to effective inhibition of P-gp and Mrp1 mediated
efflux activity in the BAB and BRB. The ERG studies indicated that both substrates, at higher
dose, induced alterations in the retina functions. However, the interactions of PTX/MTX, at the
lower dose, and P-gp inhibitors (EQ/TQ) or Mrp1 inhibitors (MK and PR) did not show any toxic
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effect on the retinal functions. The findings also suggest that prolonged exposure to the
chemotherapeutic agents above a particular dose can lead to damage to the retinal tissue.
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CHAPTER 4
COADMINISTRATION OF TOPICAL OCULAR INSERTS OF SPECIFIC
INHIBITOR MODULATES P-GP ACTIVITY IN THE BLOOD OCULAR BARRIERS AND
IMPROVES BLOOD-TO-EYE PENETRATION OF SUBSTRATE ANTICANCER DRUG

4.1.Introduction
Ocular tumors such as retinoblastoma, uveal melanoma etc. are site- and life-threating
ailments in pediatric and adult patients (126,127). Effective ocular chemotherapy is mainly
compromised by P-glycoprotein (P-gp) mediated efflux transportation of chemotherapeutic agents,
in the blood ocular barriers (BOB) (128). Upregulation of P-gp in the ocular tumors and its broad
substrate specificity restricts the efficacy of the substrate anticancer drugs (128, 76-79). Numerous
research investigations demonstrated enhanced substrate drug levels in the target organs by
effective inhibition of the P-gp activity at specific blood-organ interface (90,91,129,130). In recent
times, the third-generation specific P-gp inhibitors, elacridar (EQ) and tariquidar (TQ), were
extensively studied to modulate the P-gp activity and to improve the substrate drug molecules
penetration across the blood brain barrier or into the breast cancer cells (76, 97-99). It has been
reported that concurrent intravenous or intravitreal administration of substrate drugs and inhibitors,
like EQ/TQ demonstrated effective inhibition of P-gp activity in the blood aqueous barrier (BAB)
and blood retinal barrier (BRB) (103-105,131). However, the penetration of substrate drug into
non-specific organs due to the inhibition of P-gp activity in their plasma membrane is the major
drawback associated with concurrent intravenous administration of substrate and inhibitors (132).
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Previously, the contribution of topically administered first-generation P-gp inhibitors in
improving the blood-ocular penetration of systemically and intravitreally administered substrates
has been successfully investigated in New Zealand albino rabbits (106,107).
Ocular drug delivery via topical application, however, is restricted by various
physiological, anatomical, static and dynamic barriers (17-19). Most of the conventional
ophthalmic dosage forms, upon topical application, are washed out from the precorneal space and
thus results in poor ocular bioavailability (5-10%) (17-19). Enhancement in the viscosity and
mucoadhesive properties of the formulations prolonged their ocular residence (133). Recently,
topical ocular films were explored for sustained ocular drug delivery. They form drug depot in the
vicinity of conjunctiva and sclera tissue and thereby favors drug penetration into deeper ocular
tissues, probably through conjunctiva-sclera pathway (20,21).
In the current research, EQ and TQ loaded melt cast films were developed using
thermoplastic polymers, PolyOx® WSR N-10 (PEO), and Eudragit® FS 100 (FS), for the topical
ocular application. Physicochemical properties and transocular membrane permeability of EQ and
TQ from the inserts were evaluated. Further, for the first time, the impact of coadministration of
EQ/TQ topical ocular inserts on blood ocular penetration of substrate anticancer drug, paclitaxel
(PTX), by effective inhibition of P-gp activity in the BOB, was investigated in the Sprague Dawley
(SD) rats. Electroretinography (ERG) studies and ultrastructure analyses of retinal pigmented
epithelium (RPE) were conducted to determine the safety of PTX-EQ/TQ interactions on the
structure and functions of retina.
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4.2. Materials and Methods
4.2.1. Chemicals
PTX was procured from Sigma Aldrich (St. Louis, MO). EQ, TQ, were acquired from Alfa
Aesar (Haverhill, MA). PEO N 10 [PolyOx® WSR N-10 (PEO N-10), MW: 100,000 Daltons]
(PEO) and Eudragit® FS 100 (FS) were generously donated by Dow Chemical Company (Midland,
MI) and Evonik (Darmstdat, Germany), respectively. All other chemicals were procured from
Fisher Scientific (St. Louis, MO).
4.2.2. Animal tissues
Whole eyes of New Zealand albino rabbits were obtained from Pel-Freez Biologicals®
(Rogers, AK). They were shipped overnight in Hanks Balanced Salt Solution (HBSS) over dry ice.
On the day of receipt of Whole eye globes, corneas and sclera-retina-choroid (SRC) were excised
and utilized in the relevant experiments.
4.2.3. Animals
Six to eight-week-old male wild type SD rats, were purchased from Horizon Discovery
(Saint Louis, MO). They were allowed for free access to food and water. The animal experiments
were performed according to the approved protocols of the University of Mississippi Institutional
Animal Care and Use committee, the University of Tennessee Health Science Center Institutional
Animal Care, and Use committee and the Association for Research in Vision and Ophthalmology
statement for the Use of Animals in Ophthalmic and Vision Research.
4.2.4. Preparation of EQ and TQ loaded films
EQ and TQ loaded ocular films were prepared by melt cast technology. The physical mixtures of
inhibitor/s (EQ or TQ) and polymer/s (PEO alone or PEO:FS (1:1 w/w)) were prepared by mixing
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geometric proportions of accurately weighed excipients in the mortar with pestle.
Table 4.1: Composition of elacridar and tariquidar film formulations and evaluation parameters
Components (% w/w)

Formulation

PEO

FS

EQ

Assay (%)

TQ

Content
Uniformity
(%)

EQ PEO-FS

45

45

10

-

102.24 ± 4.92

101.42 ± 0.25

TQ PEO

90

-

-

10

99.44 ± 1.99

102.77 ± 3.86

TQ PEO-FS

45

45

-

10

84.68 ± 1.15

75.84 ± 11.56

EQ PEO

90

-

10

-

54.36 ± 1.36

57.04 ± 22.56

-

-

PEO, FS, EQ and TQ indicates poly ethylene oxide N10 (PolyOx® WSR N-10), Eudragit® FS
100, elacridar and tariquidar, respectively.
EQ-PEO-FS, TQ-PEO-FS, EQ-PEO and TQ-PEO represents elacridar film with polyethylene
oxide N10 and Eudragit® FS 100 polymers, tariquidar films with polyethylene oxide N10 and
Eudragit® FS 100 polymers, elacridar film with polyethylene oxide N10 polymer and tariquidar
films with polyethylene oxide N10 polymer, respectively
Weight of each film formulation was 200 mg

The physical mixture was then introduced into the center of 13 mm die placed on the brass plate,
maintained at 70°C on the hot plate, and compressed with 13 mm punch to form a flat film of 10%
w/w EQ or TQ load. The film was further heated for 2-3 min, cooled and cut into inserts of 1 mm
x 1 mm x 0.2 mm or 2 mm x 1 mm x 0.2 mm dimensions, weighing approximately 1mg or 2 mg,
for further experiments. The composition of the TQ and EQ films are given in Table 4.1.
4.2.5.

Analytical procedure to determine EQ and TQ
EQ content in the in vitro samples was estimated by high performance liquid

chromatography-ultraviolet spectrometry (HPLC-UV) method. A mobile phase comprising
acetonitrile (ACN) and 0.05 M ammonium acetate (45:55 % v/v), pH adjusted to 5.0 with
orthophosphoric acid, was passed through a Luna® C18(2) 100 ℃ column (Phenomenex, 4.6 mm x
250 mm; 5µ particle size), at a flow rate of 1 mL/min, by Waters HPLC system with 600 E
controller pump. 25 µL of sample was injected to the flow of mobile phase by Waters 717 plus
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Autosampler and the column eluent was monitored at λmax (detection wavelength) of 254 nm using
Waters 2487 dual λ absorbance detector. The peak response was integrated by an Agilent 3395
integrator (131, 134).
TQ content was estimated in the samples using similar chromatographic conditions except
the mobile phase consisted of acetonitrile (ACN) and 0.2 M ammonium (40:60 % v/v) and pH
adjusted to 4.5 with glacial acetic acid. The column eluents were tested at λmax of 222 nm (131,
76).
4.2.6. Assay and content uniformity
The assay of EQ or TQ ocular films was determined by dissolving the 13 mm film in 10
mL of extracting solvent, equal volumes of dimethyl sulfoxide (DMSO) and methanol. Content
uniformity was determined by dissolving four inserts randomly sliced from a single film, in
extracting solvent. The samples were diluted and quantified for the EQ and TQ content using
HPLC.
4.2.7. Differential scanning calorimetry (DSC)
DSC was performed to understand the thermal behavior and chemical compatibility of
polymers and inhibitors. DSC thermograms for EQ, TQ, PEO, FS and 10% w/w inserts were
obtained on DSC Q20 differential scanning calorimeter (TA instruments, USA). Appropriately
weighed samples were sealed in aluminum pans and heated from 0oC to 270oC at 20 oC /min
heating rate, under nitrogen purge (20 mL/min).
4.2.8. In vitro release studies
In vitro release behavior of EQ and TQ from EQ-PEO-FS and TQ-PEO ocular inserts of
2mm x 1mm x 0.2 mm dimensions was tested, as reported earlier (20,21), cross standard US 100
mesh sieve in 20 mL scintillation vials. The insert was taken in 20 mL scintillation vial and a US
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100 mesh sieve was placed on the films. 10 mL release medium (2.5 % w/v RMβCD and 1 % w/v
Tween 80 in phosphate buffer solution (PBS) (pH 7.4) was added to the vial and a stir bar was
placed over the sieve. The whole set up was placed in a thermostatic water bath (Fisherbrand™
Isotemp™ Advanced Stirring Hotplate, HN), maintained at 34°C and under constant stirring, for
2h. 1 mL sample was collected at pre-determined time intervals and replenished with same volume
of fresh medium. The samples were analyzed for the EQ/TQ content using HPLC.
4.2.9. Transocular membrane permeability studies
4.2.9.1.

In vitro transcorneal permeation study

In vitro transcorneal transport studies were performed using the corneas excised from
whole eye globes of New Zealand male albino rabbits. The corneas were mounted on the receptor
compartment of the Valia-Chien cells (PermeGear, Inc., Hellertown, PA), such that the epithelial
side face towards the donor compartment. The receptor compartment was filled with 5 mL media
(2.5 % w/v RMβCD and 1 % w/v Tween 80 in PBS (pH 7.4). 2 mg of EQ-PEO-FS or TQ-PEO
insert (equivalent to 0.2 mg of EQ/TQ) was placed on corneas and wetted with 50 µL of media in
the donor compartment. The diffusion cells were maintained at 34°C with the help of a circulating
water bath for 3h study period. Aliquots of 600 µL were withdrawn from receptor compartment at
specific time intervals and replaced with same volume of fresh medium. EQ/TQ content in the
samples and cornea tissues were estimated using HPLC.
4.2.9.2.

In vitro trans-SCR permeability study
In vitro trans-SCR (sclera-choroidal RPE) permeability of EQ/TQ was determined by using

freshly excised scleral tissue with the retinal pigmental epithelium and choroid layers, from whole
rabbit eyes. SCR was mounted on receiver compartment of Valia-Chien cells (Perme Gear, Inc®)
such that the scleral side was facing to the donor compartment and the RPE-choroidal layers were
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located towards the receptor compartment. 5 mL of media (2.5 % w/v RMβCD and 1 % w/v Tween
80 in PBS (pH 7.4) was filled in the receptor chamber. 2 mg of EQ-PEO-FS or TQ-PEO insert
(equivalent to 0.2 mg of EQ/TQ) was placed on sclera and wetted with 50 µL of media in the donor
compartment. The diffusion cells were maintained at 34°C with the help of a circulating water bath
for 3h study period. Aliquots of 600 µL were withdrawn from receiver compartment at specific
time intervals and replaced with same volume of fresh medium. EQ/TQ content in the samples and
SCR tissue were estimated using HPLC.
4.2.10. Data Analysis
The transocular permeability parameters of EQ/TQ such as the cumulative amount of drug
permeated (Mn), steady state flux (J) and the apparent permeability coefﬁcient (Papp) were estimated as
previously reported (135). Equations 1 was used to integrate the cumulative amount of EQ/TQ permeated
across the cornea or SCR.

∑

(1)

Where: n specified sample time interval (n = 1, 2, 3….8 corresponding to 15, 30, 45….180 min
respectively); Vr and VS indicates the media volume in the receptor compartments (mL) and sample
the volume collected at the nth time interval (mL); and Cr(n) represents the EQ/TQ concentration in
the receptor compartment medium at nth time interval (µg/mL).
The slope of the cumulative EQ/TQ permeated vs. time (t) plot was determined to calculate
the steady-state flux (SSF) (J) of EQ/TQ was using equation 2:
/ " /#

(2)

Where M and A specifies the cumulative amount of drug transported and the surface area of the
cornea or SCR utilized in the experiment (0.636 cm2).
3. The apparent permeability of EQ/TQ across the cornea or SCR was determined from the ratio of
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steady state flux (J) and EQ/TQ amount in the donor compartment (Cd) (Eq. (3)) (26, 30).
$%&&

'()

*

(3)

+, ∗./

4.2.11. P-gp protein expression by western blotting
The expression of P-gp protein in the BAB and BRB of the SD rats was studied by western
blotting. The SD rats were euthanized with excess intraperitoneal (IP) dose of ketamine (35 mg/kg)
and xylazine (3.5 mg/kg) combination (n=6), the eyes were enucleated, and immediately the ocular
tissue (Iris Ciliary (IC) and Retina choroid (RC)) samples were collected. IC and RC tissues lysates
were prepared using 2X lysis buffer (Cell Signaling Technology, USA). Tissue lysates were
measured for protein concentrations by Bradford assay (Bio-Rad USA). 20 µg of proteins, from
each tissue lysate, were taken into the wells of 10% SDS-PAGE mini-gels (Bio-Rad, USA) and
electrophoresed. Then proteins were transferred to nylon membranes (Cell Signaling Technology,
USA) according to standard western blot protocol. These membranes were blocked in 5% non-fat
dried milk in 1X TBST [20 mM Tris–HCl (pH 7.5), 137 mM NaCl and 0.1% (v ⁄ v) Tween 20] for
1h at room temperature. Blots were kept overnight with primary antibody MDR1/ABCB1 (Cat #
13978 Cell Signaling Technology) as per the manufacturers protocol. After washing the
membranes with 1X TBST, they were probed with anti-rabbit secondary antibody conjugated to
HRP (Cat # 7074 Cell Signaling Technology) for 1h. To ensure equal loading, samples were added
with β actin antibody (Cell Signaling Technology, USA). The blots were developed with signal
flame enhanced chemiluminescence (ECL) TM kit (Cell Signaling Technology, USA). The images
were captured, processed and analyzed on ChemiDoCTM MP imaging system (Bio-Rad, USA).
Protein band area was computed by using ImageJ and, the ratio of P-gp band area and the
corresponding β-actin band area was calculated as relative P-gp protein intensity.
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4.2.12. Electroretinography
To determine the PTX-EQ or TQ interactions with the retina functions, electroretinography
(ERG) studies were performed in SD rats. 12 SD rats were divided into 2 groups and one group
was topically administered with 1 mg EQ-PEO-FS insert (equivalent to 0.1 mg EQ) in each eye
while the other group received 1 mg TQ-PEO insert (equivalent to 0.1 mg TQ) in each eye. During
the administration of EQ or TQ inserts, the rats were partially anesthetized with ketamine (35
mg/kg) and xylazine (3.5 mg/kg) combination through IP route. Post 30 min EQ/TQ administration
in the eyes of the rats in both the groups, they were injected with a specific volume of 3 mg/mL
PTX solution (equivalent 1 mg/kg intravenous dose).
ERG was performed as per the standard protocols (115,116). The overnight darkadapted rats were anesthetized with an I.P. injection of ketamine and xylazine combination. Both
the corneas were anesthetized with topical 0.5% proparacaine hydrochloride, the pupil was dilated
with 1% tropicamide and gold ring electrodes of 2-3 mm diameter (Roland Consult, Stasche &
Finger GmbH), were placed on corneas. Stainless-steel surgical needles were inserted
subcutaneously in the forehead and back leg to serve as reference and ground electrodes
respectively. Both the eyes were exposed to Ganzfeld light source flashes of different intensities
(from −4.0 Log units to 2.88 Log units) and the dark-adapted ERG patterns were measured. The
baseline a- wave and b-wave amplitudes were recorded in the rats before the administration of
EQ/TQ inserts. The differences in the a- and b- waves amplitudes recorded as baseline and at the
of 6h or 12h post PTX (1 mg/kg) treatment were reported as percentage change in the amplitude.
4.2.13.

Ultrastructural analyses of retina pigmental epithelium

Ultrastructural analyses of the retina was performed, as per the standard protocols (115,
131), to evaluate the PTX-EQ/TQ interactions with the structure of the retina. Post ERG studies,
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the rats from 2 treatment groups were euthanized with excess of ketamine and xylazine
combination, the eyes were enucleated and were fixed with a 2% paraformaldehyde and 2%
glutaraldehyde mixture in 0.1 M phosphate buffer. These eyes were then embedded in
Araldite/Embed812 (Electron Microscopy Sciences) and the anterior-posterior axis of the eye were
aligned parallel to the cutting surface block and sections of one-micron thick were sliced through
the posterior pole of each eye. The tissue sections were stained in Toluidine Blue O and then seen
under a Nikon Eclipse 800 microscope to select the suitable tissues section area for ultrastructural
analyses of RPE and retinal blood vessels. These ultrathin sections were observed for any structural
changes in the RPE or the retinal vasculature under JEOL JEM1200EX II electron microscope at
high magnification.
4.2.14. Ocular distribution
Ocular distribution studies were undertaken in male SD rats to establish the impact of coadministration of specific P-gp inhibitor loaded topical ocular inserts on the blood ocular
penetration of PTX through effective modulation of P-gp activity in the BOB. No gender
dependent transporter protein expression in the ocular tissues were reported in the literature, thus,
the current study was conducted in only male SD rats. 60 SD rats were divided into 2 treatment
groups with equal number of rats. Each rat in the first group was administered with 1 mg of EQPEO-FS insert (equivalent to 0.1 mg EQ) topically in each eye. The second group rats were
administered with topical 1 mg TQ-PEO insert (equivalent to 0.1 mg TQ) in each eye. The rats in
each group were partially anesthetized with IP ketamine (35 mg/kg) and xylazine (3.5 mg/kg)
combination before the administration of EQ/TQ insert, and they were conscious in 5-10 min post
EQ/TQ administration. After 30 min from the EQ/TQ administration, rats in two groups were
administered with 1 mg/kg dose of PTX intravenously through tail vein. At 1, 2, 4, 6 and 12h post
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PTX treatment, rats (n=6 at each time point) from each group were anesthetized with an I.P.
administration of ketamine (35 mg/kg) and xylazine (3.5 mg/kg) mixture, blood was collected via
cardiac puncture and were euthanized with excess of ketamine and xylazine combination through
I.P. route. The eyes were enucleated immediately. Aqueous humor (AH) and vitreous humor (VH)
were collected from both eyes of each rat and was pooled. The blood samples collected were
immediately centrifuged at 10,000 rpm for 5 min and the plasma was separated. Plasma, AH and
VH samples were stored at -80oC until analysis.
Another group of 12 SD rats, not pretreated with either EQ or TQ insert, were
injected with 1 mg/kg dose of PTX through tail vein. At 1h and 2h post PTX dosing, the rats (n=6
at each time point) were processed similarly as mentioned earlier and the plasma, AH and VH
samples were collected and stored at -80oC until analysis.
4.2.15. Sample Preparation
10 µL, 2.5 µL, and 5 µL of 1 µg/mL docetaxel (DTX) (internal standard (IS) for PTX) and
1 µg/mL loperamide (LOP) (internal standard (IS) for EQ and TQ) solutions were added to 80 µL
plasma, 20 µL AH and 40 µL VH tissue samples, respectively. The proteins in 1 part of sample
tissue matrix was precipitated with 2 volumes of ice-cold acetonitrile to extract PTX or EQ and
TQ and IS. These samples were vortexed, centrifuged at 13000 rpm for 15 min and the supernatant
solution was separated. The PTX, EQ, TQ and their respective IS in the supernatant solution (2
μL) were quantified by the following LC/MS method. The extraction efficiency (EE), limit of
detection (LOD) and linearity of PTX, EQ and TQ in plasma (10-100 ng/mL), AH (0.5-40 ng/mL)
and VH (0.5-20 ng/mL) was evaluated separately.
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4.2.16. Quantification of PTX, EQ and TQ in the biological matrix
The quantity of PTX, EQ and TQ in the plasma, the AH and the VH samples were
determined with the ACQUITY UPLC® I-Class System (Waters Corporation, Milford, MA, USA)
connected to Waters Xevo TQ-S triple quadrupole tandem mass spectrometer with an electrospray
ionization (ESI). Data acquisition and processing were controlled by Waters Xevo TQ-S
quantitative analysis TargetLynx software and MassLynx mass spectrometry software,
respectively.
Separation of PTX was achieved on an Acquity UPLCTM Cortecs C18 (2.1x100
mm; 2.7 µm) column with operations were accomplished using a C18 column (Acquity UPLC®
BEH C18 100 mm×2.1 m, 1.7µm particle size). The mobile phase comprised of water (A) and
acetonitrile (B), both containing 0.1 % formic acid, at a flow rate of 0.7 mL/min, which were
applied in the following gradient elution: 0 min, 55 % A: 45% B, in next 2.5 min to 50% B, and
next 0.2 min to 100 % B, and then to 55% A for next 2.5 min. Each run was followed by a 3 min
wash with 100 % acetonitrile, and an equilibration period of 1 min. The column temperature was
set at 50 °C. Two microliters of sample was injected into the column and the effluent was directed
into the ESI probe (source) operated using following parameters: source temperature 60°C,
desolvation temperature 600°C, capillary voltage 2.0 kV, cone voltage 30 V, nebulizer pressure-7
bar, desolvation gas flow 1200 L/h N2 and cone gas flow 150 L/h N2. The collision energies ranging
from 20 to 64 eV were optimized, for individual analytes. Argon served as the collision gas. All
the instrument operations were controlled by MassLynx software (version 4.1, Waters, Milford,
MA, USA). Mass spectra of each sample was acquired in positive mode. The precursor to daughter
ions transitions (quantifier ion to qualifier ions transitions) of PTX (m/z 854.31 → m/z 286.14,
122.08, 195.06) and DTX m/z 808.37 → m/z 527.23, 327.15, 105.06) was monitored in multiple
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reaction monitoring (MRM) mode. The compounds were confirmed in each spectrum by the three
daughter ions, each for PTX and DTX.
The peaks of the EQ, TQ and LOP (IS) were quantified with respect to the specific
mass to charge (m/z) values (m/z 564, 647 and 477 for EQ, TQ and LOP, respectively). The
samples were eluted through BEH C18 (2.1 x 100 mm, 1.7 µm) column and separated using an
isocratic mobile phase consisting of with 0.1% v/v formic acid and water with 0.1% v/v formic
acid. The method showed a limit of detection (LOD) and limit quantification of (LOQ) of 0.1
ng/mL for EQ and TQ.
4.2.17. Data Interpretation
PTX distribution into the AH and VH from plasma was calculated according to equations
1 & 2 respectively,
012
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Where, DAH and DVH designates the distribution ratios delineating the penetration of PTX
from plasma into AH and VH, respectively.
4.2.18. Statistical analysis
The data from ERG and ocular distribution studies were processed through one-way
analysis of variance (ANOVA) and Tukey’s post hoc HSD (GraphPad Software, San Diego
California, USA), to establish the statistical signiﬁcance. The p < 0.05 were considered statistically
significant.
4.3. Results and Discussion
Melt-cast method, a simple and solvent free technique, was adopted to fabricate the ocular
films of EQ and TQ (20, 21). In these ocular films, molecular level drug entrapment in carrier
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matrix results in higher drug loading. Unlike the conventional ophthalmic dosage forms, the use
of excipients such as preservatives are not necessary in the melt cast ocular films (26, 27). PEO
and FS, thermoplastic polymers, were used as matrix forming materials due to the thermogelling
property and pH 7.4 dependent drug releasing characteristic, respectively (20, 136).
4.3.1. Assay and content uniformity
The assay and content uniformity of the EQ and TQ films are detailed in Table 4.1. EQPEO film showed low assay (54.3%) and content uniformity (57%) due to the manufacturing issues
like sticking of EQ to motor and picking by 13 mm punch during the film preparation (Table 4.1).
No such manufacturing issues were noticed while developing EQ-PEO-FS film and thus, resulted
in ~ 100% assay and content uniformity (Table 4.1). On the other hand, loss of TQ was noticed in
the development of TQ-PEO-FS film and resulted in low assay (84.68%) and content uniformity
(75.84%) (Table 4.1). TQ-PEO film showed acceptable 99.44% assay with uniform distribution of
TQ in the PEO matrix suggesting the lack of sticking and picking issues while manufacturing
(Table 4.1). EQ-PEO-FS and TQ-PEO films with acceptable assay and uniform distribution of
compounds in the polymeric matrix were considered for further studies.
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4.3.2. DSC

Figure 4.1: DSC thermograms of PEO N10, FS, EQ, TQ, EQ-PEO-FS insert and TQ-PEO insert.

DSC studies were performed to investigate the thermal behavior and excipient
compatibility of TQ-PEO and EQ-PEO-FS ocular inserts. DSC thermograms of EQ, TQ, PEO, FS
and PEO-FS (1:1 w/w), TQ-PEO and EQ-PEO-FS are displayed in Figure 4.1. The endothermic
peaks seen at 69.49°C and 55.99°C in the PEO and FS thermograms, respectively, corresponds to
their melting points (Fig. 4.1). Pure EQ and TQ showed the melting peaks at 227.21°C and
229.03°C, respectively (Fig 4.1). TQ-PEO and EQ-PEO-FS ocular inserts exhibited a melting
point peak at 67°C. The absence of native endothermic peak of Eq and TQ in the films indicated
the reduction in crystallinity of inhibitors in the polymeric frameworks (Fig. 4.1). No significant
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shifts in the characteristic melting points of the polymers and inhibitors in the ocular inserts
suggested absence of chemical interactions between the film components.
4.3.3.

In vitro release of EQ and TQ
In vitro release profile of EQ and TQ from ocular inserts are presented in Figure 4.2. In

Figure 4.2: In vitro release profiles of EQ and TQ from EQ-PEO-FS and TQ-PEO ocular inserts, respectively
(mean ± SD; n=6)

vitro release behavior of these P-gp inhibitors were studied in PBS (pH 7.4) with 2.5 % w/v
RMβCD and 1 % w/v Tween 80 (pH 7.4) due to relatively high solubility of both EQ (20.14 ±
0.93 µg/mL) and TQ (12.16 ± 0.30 µg/mL). At the end of 2h, the % cumulative release of EQ and
TQ, from EQ-PEO-FS and TQ-PEO inserts, were 92.35 ± 4.57 and 87.54 ± 2.56%, respectively
(Fig. 4.2). The release of EQ from EQ-PEO-FS insert was comparatively slower than TQ from
TQ-PEO insert (Fig. 4.2) which could be attributed to the presence of FS polymer, that helps drug
release only at pH 7.0, in EQ-PEO-FS insert (136).
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4.3.4. Transocular permeability
In vitro transocular membrane permeability parameters of EQ and TQ are given in Table
4.2. Both EQ and TQ showed transcorneal permeability but no penetration was noticed across the
Table 4.2: In vitro transocular membrane permeation parameters of elacridar and tariquidar from film
formulations (mean ± SEM; n=3)

Films

10 % w/w
EQ- PEO-FS
10 % w/w
TQ- PEO

Transcorneal permeability
parameters
P x 106
Amount in

Flux
(µg/cm2/min)

(cm/s)

cornea (µg)

0.016 ± 0.003

1.3 ± 0.3

30.7 ± 9.6

NS

NS

156.9 ± 3.44

0.04 ± 0.01*

5.9 ± 2.4*

36.3 ± 0.4

NS

NS

112.7 ± 0.5

app

Flux
(µg/cm2/min)

Trans-SCR permeability
parameters
P x 106
Amount in
app

(cm/s)

SRC (µg)

- PEO, FS, EQ and TQ indicates poly ethylene oxide N10 (PolyOx® WSR N-10), Eudragit® FS 100, elacridar
and tariquidar, respectively.
- EQ-PEO-FS and TQ-PEO represents elacridar film with polyethylene oxide N10 and Eudragit® FS 100
polymers, and tariquidar films with polyethylene oxide N10 polymer, respectively
- SCR and Papp represents sclera-choroidal RPE and apparent permeability coefficient, respectively
- Weight of each film formulation was 200 mg
- *-indicates level of significance at p<0.05between transocular membrane permeability of EQ-PEO-FS and
TQ-PEO

SCR (Table 4.2). The steady state flux and Papp of TQ-PEO inserts (0.040 ± 0.01 µg/cm2/min and
5.6 ± 2.4 x 10-6 cm/s), across the rabbit cornea, were significantly higher than EQ-PEO-FS inserts
(0.016 ± 0.003 µg/cm2/min and 1.3 ± 0.3 x 10-6 cm/s). This could be attributed to the higher Log
D7.4 and topological polar surface area of TQ (5.39 & 111.25 A2) compared to EQ (3.9 & 89.1 A2).
It has been demonstrated in the literature that the transmembrane permeability of a compound
decreases with the decrease in Log D7.4 and the compounds with higher polar surface area can
penetrate through the hydrophilic stroma layer in the cornea (137, 138). Additionally, the slow
release of EQ from EQ-PEO-FS inserts, compared to TQ from TQ-PEO insert, could have resulted
in its lower transcorneal permeation. The SCR tissues treated with corresponding inserts showed
EQ and TQ levels suggesting the lateral diffusion of these P-gp inhibitors in the sclera, but they

87

did not penetrate across the choroidal RPE (Table 4.2). The levels of EQ in the SCR tissue was
significantly higher compared to TQ in TQ-PEO treated SCR tissues which could be due to the
high the molecular weight of TQ (646 g/moL), compared to EQ (563 g/moL) (Table 4.2). Earlier
reports demonstrated poor sclera penetration of high molecular weight compounds (20, 21).
4.3.5. Electroretinography (ERG)
ERG was carried out to investigate any toxic effects of PTX-EQ/TQ ocular insert
interactions on the functions of photoreceptor cells in the outer segment of the retina and inner
retinal cells. The a-wave and b-wave recordings noted in the ERG represents the functioning of
photoreceptor cells and bipolar/Müller cells, respectively. Any changes in the a- and b-wave
patterns indicate the damage to the outer retina and the inner retina (114-116). The percent change

Figure 4.3: A) Percent changes in the amplitude of ERG wave patterns recorded in the EQ-PEO-FS and TQ-PEO
treated rats, at 6h and 12h post PTX (1 mg/kg) intravenous administration (mean ± SEM; n=3).

in the amplitude of a- and b-wave examined in the SD rats are delineated in Figure 4.3.
No significant changes in the a- and b-wave amplitudes were observed, with respect
to baseline measurements, in the rats treated with EQ-PEO-FS (equivalent EQ 100µg/eye) and
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TQ-PEO (equivalent TQ100µg/eye) ocular inserts, post 6h and 12h PTX (1 mg/kg) intravenous
administration, (Fig. 4.3). Thus, ERG studies confirmed that the tested doses of EQ-PEO-FS, TQPEO, and PTX did not induce any toxic effects on the functions of the retina.
4.3.6. Ultrastructure analysis of RPE
Figure 4.4 illustrates the ultrastructure of the RPE in rats co-administered with PTX and
EQ-PEO-FS or TQ-PEO. RPE was observed under TEM for any morphological changes in
choriocapillaris (Ch), Bruch’s membrane (BM), basolateral infoldings of RPE (BNF), pigmented
granules (PG), and RPE nucleus. Diffused Ch, reduced BM thickness, absence of BNF, loss of
pigmented granules (PG), and appearance of vacuoles in the RPE indicates the damage to retina
architecture (139,140). No such observations were noticed in the ultrastructure of RPE in rats
topically administered with EQ-PEO-FS and TQ-PEO ocular inserts, at the end of 6h and 12h post
PTX (1 mg/kg) IV administration (Fig. 4.4). Moreover, the ultrastructure of RPE in rats pretreated
with EQ ocular insert were not different from those treated with TQ-PEO insert (Fig. 4.4). These
findings suggested that the PTX-EQ/TQ interactions, at tested doses, did not compromise the
structural integrity of retina.
4.3.7. Ocular distribution
Ocular distribution studies were performed to investigate the potential of topical ocular
delivery of EQ-PEO-FS and TQ-PEO inserts to improve the blood-ocular penetration of substrate
anticancer drug, PTX, by effective modulation of P-gp activity in the BOB. To ensure the
inhibition of P-gp activity in the BOB, the rats were pretreated with EQ or TQ inserts 30 min prior
to PTX dosing. The ocular pharmacokinetic profile of PTX in the rats co-administered with topical
EQ and/or TQ ocular inserts is represented in Figure 4.5. The ocular pharmacokinetic parameters
of PTX and P-gp inhibitors (EQ/TQ) are enumerated in Table 4.3 and Table 4.4, respectively.
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respectively. Ch-choriocapillaris; RPE-retinal pigmented epithelium; BM-Bruch’s membrane; BNF-basolateral infoldings of RPE; PG-pigmented granules.

at 6h (A & C) and 12h (B & D), respectively, post intravenous administration of PTX (1 mg/kg). i and ii – indicates the magnification of 2 µm and 500 nm,

Figure 4.4: TEM images focusing ultrastructure of retinal pigmented epithelium (RPE) in rats administrated with EQ-PEO-FS and TQ-PEO ocular inserts, taken

Plasma PTX concentration profile seen in the rats from both EQ-PEO-FS and TQ-PEO
groups were not statistically different (Fig. 4.5A). The AH PTX concentration profile seen in the

Figure 4.5: Pharmacokinetic profile of PTX in A) plasma, B) AH and E) VH of rats co-administered with EQ-PEOFS and TQ-PEO topical ocular inserts. D) Distribution of PTX from plasma to AH (DAH) and VH (DVH) in rats
treated with intravenous PTX (1 mg/kg) alone and C) DAH, and F) DVH of PTX in rats co-administered with EQ and
TQ ocular inserts (mean ± SEM; n=6).

rats treated with TQ inserts were significantly higher (p<0.05), till 4h post PTX administration,
over that seen in EQ treated rats (Fig. 4.5B). Similarly, the DAH PTX observed in rats treated with
TQ-PEO inserts were comparatively higher (p<0.05), in first 4h post PTX injection, than that
noticed in the rats administered with EQ-PEO-FS ocular inserts (Fig. 4.5C). The PTX levels in the
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AH of rats treated with PTX (1 mg/kg) alone were below the detectable limits whereas DAH PTX
in both EQ and TQ pretreated rats were significantly higher (p<0.05) compared to that found in
Table 4.3: Ocular pharmacokinetic parameters of paclitaxel post intravenous administration in wild type rats
co-administered with topical ocular films of EQ and TQ (mean ± SEM; n=6)
PTX (1 mg//kg) + EQ

Pharmacokinetic

(100 µg/eye)

parameters

VH

AH

VH

31.5 ± 2.5

35.3 ± 4.6

39.5 ± 2.3

34.7 ± 1.6

t ½ (h)

2.4 ± 0.4

2.3 ± 0.5

1.9 ± 0.2

2.0 ± 0.3

MRT (h)

3.1 ± 0.4

3.1 ± 0.3

3.0 ± 0.2

3.0 ± 0.4

(ng h/mL)

-

µg/eye)

AH

AUC0-12

-

PTX (1 mg//kg) + TQ (100

PTX, EQ, TQ, AH and VH indicates paclitaxel, elacridar, tariquidar, aqueous humor and vitreous
humor, respectively
AUC, t ½ and MRT represents area under curve, elimination half life and mean residence time,
respectively

these rats and confirmed the effective inhibition of P-gp activity in the BAB (Fig. 4.5C & Fig.
4.5D). These results corroborate with the earlier literature reports which demonstrated the
Table 4.4: Ocular pharmacokinetics of EQ and TQ in wild type rats administered with topical ocular film
formulation (mean ± SEM; n=6)
Pharmacokinetic

EQ (100 µg/eye)

TQ (100 µg/eye)

parameters

AH

VH

AH

VH

AUC0-12 (ng h/mL)

77.0 ± 2.8*

82.9 ± 4.6*

36.5 ± 2.8

12.5 ± 1.1

t ½ (h)

2.8 ± 0.5

4.2 ± 0.8*

2.6 ± 0.4

1.8 ± 0.6

MRT (h)

4.5 ± 0.8

5.2 ± 0.7*

5.8 ± 0.6

3.5 ± 0.3

-

EQ, TQ, AH and VH indicates elacridar, tariquidar, aqueous humor and vitreous humor, respectively

-

AUC, t ½ and MRT represents area under curve, elimination half life and mean residence time,
respectively

-

*-indicates the level of significance at p<0.05 between pharmacokinetic parameters seen EQ (100
µg/eye) and TQ (100 µg/eye) treated rats

enhanced penetration of substrate drug into the AH due to the effective modulation of the P-gp
expression in the BAB, post concurrent intravenous or intravitreal administration of P-gp substrate
and inhibitor (103,104, 131). The PTX profiles in the VH of rats administered topically with either
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EQ-PEO-FS and TQ-PEO ocular inserts were similar (Fig. 4.5E). Thus, the DVH PTX in both EQ
and TQ treated rats were not statistically different (Fig. 4.5F). On the other hand, no drug
penetration was noticed from plasma to VH of the rats administered with PTX alone (Fig. 4.5D).
Hence, the DVH PTX in rats from both EQ-PEO-FS and TQ-PEO treatment groups were
significantly higher (p<0.05) compared to the rats treated with PTX alone suggesting an improved
blood-to-VH penetration of substrate anticancer drug by inhibiting the P-gp activity in the BRB,
as reported in the earlier literature (105-107,131).
AUC of PTX in the AH of rats administered with TQ (39.5 ± 2.3 ng. h/mL) was
slightly higher, but statistically not different, compared to that found in the rats treated with EQ
(31.5 ± 2.5 ng. h/mL) (Table 4.3). The AUC of EQ and TQ in the AH of rats treated with P-gp
inhibitor loaded ocular inserts were 77.5 ± 2.8 ng h/mL and 36.5 ± 2.8 ng h/mL, respectively (Table
4.4). Even at ~2 fold lower AUC in AH of rats, TQ produced P-gp inhibitory effect similar to that
of EQ and hence, no statistical difference was noticed in the AUC of PTX in the AH of rats from
both EQ and TQ treatment groups. Similarly, at 2-6 fold lower AUC of TQ in VH, rats treated with
TQ showed similar AUC of PTX in VH compared to that found in EQ treated rats (Table 4.3 and
Table 4.4). These results can be related to high affinity of TQ (IC50 ≤ 0.05 µM) for P-gp compared
to EQ (IC50 ≤ 0.1 µM) (95). It has been reported that the TQ modulates the P-gp efflux activity
by blocking both drug and ATP binding sites, whereas, EQ blocks only the drug/substrate binding
site in the P-gp structure (97,121). Hence, TQ showed effective inhibition of P-gp activity in the
BOB and thus, enhanced the blood ocular penetration of PTX.
The DAH and the DVH of PTX in the rats treated with TQ-PEO insert was reduced,
after 4h timepoint, while they sustained for 6h in the rats administered with EQ-PEO-FS inserts
(Fig. 4.5C and Fig. 4.5F). This can be related to the elimination half-life (t ½) of TQ and EQ, in
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the AH and the VH of rats. The t ½ of TQ in AH and VH was short whereas the EQ was longer in
these ocular tissues (Table 4.4). The longer t ½ of EQ in the AH and the VH could be attributed to
the slow release of EQ due to the presence of FS polymer which helps drug release at pH 7.0 (136,
21). TQ-PEO and EQ-PEO-FS ocular inserts form a localized depot in the vicinity of conjunctivalscleral tissue and thereby distribute into the deeper ocular compartments (20, 21). Hence, the MRT
of EQ and TQ in the AH and VH was 4.5-5.8h ensuring the blood ocular penetration of PTX for
6h by effective modulation of P-gp activity in the BOB (Table 4.4).
4.4. Conclusion
EQ and TQ loaded ocular inserts were successfully prepared by hot melt technology using PEO
and FS thermoplastic polymers as matrix forming materials. TQ-PEO and EQ-PEO-FS ocular
inserts showed acceptable assay and content uniformity. These ocular inserts showed ~ 90 %
cumulative amount of EQ and TQ release in the in vitro release studies. Both EQ and TQ
demonstrated the transcorneal permeability characteristics but poor trans-SCR permeability
behavior. ERG studies and ultrastructure analyses of RPE revealed that the PTX, a substrate
anticancer drug, and EQ/TQ interactions did not induce any toxic effects on the structure and
functions of retina. Improved penetration of PTX into the AH and the VH from systemic
circulation indicated the effective inhibition of P-gp activity in the BOB and exemplified the
concurrent administration of topical ocular inserts of EQ/TQ, and intravenous anticancer substrate
drug, as a potential strategy to enhance the ocular chemotherapy.
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CHAPTER 5
EYELID APPLICATION OF TRIAMCINOLONE PROTRANSFERSOME GEL FOR
IMPROVED AND PROLONGED OCULAR DELIVERY
5.1. Introduction
Inflammation of the anterior and posterior segment ocular tissues are often associated with
most of the eye ailments (140). Numerous steroidal and non-steroidal anti-inflammatory agents
are being used for the management of ocular inflammations (141). Triamcinolone acetonide (TA)
is a potent synthetic corticosteroid utilized to ameliorate the inflammation of ocular compartments
(141). Currently, TA is available in the market as an intravitreal injection (Kenalog®, Kenacort®,
Tricinolon®, Flutex®) for the treatment of deeper ocular tissue inflammations (140,142). Despite
efficient therapy, intravitreal drug delivery encounters poor patient compliance due to post
injection associated complications such as retinal detachment, postoperative infections etc. (19,
144-146). Thus, topical ocular drug delivery is a more preferred route of administration. However,
the ocular bioavailability of topically instilled drugs is hampered by various anatomical and
physiological, constraints (19,133).
In recent times, drug delivery through the eyelid has been investigated as an
alternative, noninvasive, drug delivery platform that can maintain and sustain therapeutic drug
levels in the eye (147-150). The thickness of the skin and stratum corneum on the eyelid is very
thin compared to the skin in any other region (148,149,151). The drug applied to the upper eyelid
penetrates into the conjunctiva and from there it will move into the inner ocular tissues, either
through the corneal or through the scleral route (147-150).
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It is also likely that this route of administration will maintain a steady drug concentration
in the tear film (148). To the best of our knowledge, there have been few literature reports that
studied trans-eyelid drug delivery (147-150). The data demonstrated prolonged drug levels on the
ocular surface following application of a semisolid dosage form applied on the eyelid compared
to the conventional formulation instilled in the eye (147,150).
Protransfersome gels were extensively explored for superior transdermal drug
delivery (152). These formulations rapidly convert into transfersomes, ultradeformable and
ultraflexible vesicles, by absorbing water from the skin, and efficiently penetrates into the deeper
skin layers (43,152-155). Unlike the proliposome and proniosome systems, these gels have an edge
activator alongside the vesicle forming components, which provides the flexibility to the
transfersomes and, thus, enhances the transcellular permeation across the intact skin (43,156-159).
Various mechanisms have been proposed to explain the ability of vesicles to modify drug diffusion
through the skin (156-160). Principally, fluidization of the regular skin structure, because of the
inclusion of the vesicle into the intercellular lipid layers of the skin, is important in overcoming
the barrier property of the stratum corneum (157-161). The higher concentration gradient, between
the skin and drug loaded vesicles, is another driving force that improves drug permeation through
the skin (152,157-161).
The effectiveness of a protransfersome gel formulation for eyelid drug delivery,
loaded with TA, has not been investigated till date. Thus, the goal of the current research was to
develop and investigate the TA loaded protransfersome gel (PTF) as effective eyelid drug delivery
system for improved ocular pharmacotherapy.
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5.2. Materials and Methods
Phospholipon 90H (PL) was procured from Lipoid, LLC (Newark, NJ, USA), Kolliphor
TPGS (D-alpha tocopheryl polyethylene glycol 1000 succinate) was obtained from BASF
Corporation (NJ, USA), (Sorbitan monostearate (Span 60 (S60)) was received from Sigma Aldrich
(St. Louis, MO, USA. Cholesterol (CH) was procured from Alfa Aesar (Ward Hill, MA, USA).
TA, Amicon® Ultracentrifugal filter devices with regenerated cellulose membrane (molecular
weight cut off 100 kDa), high performance liquid chromatography (HPLC) - grade solvents, and
other chemicals (analytical grade) were supplied by Fisher Scientific (Hampton, NH, USA).
5.2.1. Preparation of TA loaded Protransfersome gels
PTF were manufactured as per previously reported technique (152,158). Briefly, the
quantities of TA, the vesicle forming components (PL, CH and S60) and, the edge activator
Table 5.1: Composition of TA protransfersome gels and their physicochemical evaluation parameters
(mean± SD; n=3).

-

Component/Evaluation
parameter
TA (mg)
PL (mg)
CH (mg)
S60 (mg)
TPGS (mg)
Ethanol (mg)
Water (mg)
Assay (%)

PTF 1

PTF 2

PTF 3

10
200
34
30
30
100
500
92.1 ± 3.2

10
200
34
30
30
200
500
94.5 ± 2.6

10
200
34
30
30
400
500
95.7 ± 2.2

Content Uniformity (%)

80.2 ± 11.5

89.5 ± 3.1

92.4 ± 2.7

366.4 ± 6.6
184.5 ± 6.8
235.5 ± 4.6
Particle size (nm)
0.52 ± 0.13
0.30 ± 0.08
0.30 ± 0.05
PDI
- 21.7 ± 1.7
-21.4 ± 2.3
- 25.3 ± 3.6
ZP
64.3 ± 4.4
89.4 ± 2.2
76.4 ± 2.1
%EE
TA, PL, CH, S60 and TPGS indicates, triamcinolone acetonide, phospholipon 90H, cholesterol,
span 60, and TPGS, respectively.

-

ZP and %EE represents zeta potential and % entrapment efficiency, respectively.

(TPGS) were accurately weighed in a clean glass vial and then, appropriate volume of
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alcohol was incorporated. Later, the glass vial was closed with the screw cap and placed in
a water bath maintained at 60-700 C.
The contents in the glass vial was melted to form a homogenous viscous fluid, to which,
appropriate quantity of water (maintained at same temperature) was added in a dropwise manner
with constant mixing till the translucent gel was formed. Further, the PTF was allowed to attain
room temperature and utilized for further studies. The composition of PTF formulations is given
in Table 5.1.
5.2.2. Quantification of TA in in vitro samples
TA content in all the in vitro samples were analyzed using high performance liquid
chromatography (HPLC) method reported earlier (162). The HPLC system comprising of Waters
717 plus auto sampler, Waters 2487 dual absorbance detector, 600 Waters controller pump, and
an Agilent 3395 Integrator. A mobile phase of a 1:1 isocratic solution of water and acetonitrile was
passed through a Luna® C18 (4.6 mm × 250 mm) column at a flow rate of 1 mL/min; 25µL of
sample was injected into the mobile phase and, the column eluents were detected for TA at
wavelength (λmax) of 254 nm.
5.2.3. Assay, Content Uniformity and Entrapment Efficiency
To determine the assay and content uniformity in the PTF, known amount of formulation
was dissolved in methanol and centrifuged (AccuSpin 17R centrifuge, Fisher Scientiﬁc, USA) at
13,000 rpm for 15 min. The supernatant was separated, and TA content was quantified using
HPLC.
Entrapment efficiency (EE (%)) was determined by dispersing known amount of PTF
(equivalent 1 mg TA) in 1 mL water and then vortexed to form a homogenous dispersion. Further,
a 500 uL aliquot of this dispersion was added to the sampler holder in 100-kDa centrifugal filter
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unit (Amicon Ultra) and centrifuged at13,000 rpm for 15 min. The drug in the filtrate was estimated
by HPLC method and the %EE was calculated by using the equation 1:
0D EE
0

E

F7 − F8
HX
F7

//

1

Where, wi is the total drug content and wf is the free drug present in the aqueous phase.
5.2.4. Morphometric characterization
The hydrodynamic radius, zeta potential (ZP) and polydispersity index (PDI) of the
transfersomes formed from the PTF formulations were determined by photon correlation
spectroscopy using a Zetasizer Nano ZS Zen3600 (Malvern Instruments, MA, USA) at 25°C in
clear, disposable folded capillary cells. Known amount of PTF formulation was dispersed in 1 mL
of water and vortexed to get a homogenous dispersion. This transfersome dispersion was diluted
10,000 times with bi-distilled water, and the particle size and PDI measurements were obtained
using a helium-neon laser of 633 nm. Zeta potential (ZP) measurements were also carried out at
25°C using the laser Doppler velocimetry function of the same instrument.
5.2.5. Polarized Microscopy
The crystalline nature of pure TA and the protransfersome gels was observed under optical
polarized microscopy, as reported earlier (163,164). Briefly, the test samples were placed on the
rectangular cover slips and then loaded onto the optical microscope with uncrossed polarizer
(Nikon Eclipse E600 Pol, Nikon Instech Co., Japan). The images with optical birefringence of
drug was recorded.
5.2.6. Optical microscopy to observe the formation of transfersomes from PTF
The formation of transfersomes from PTF was observed under optical microscopy, as
reported earlier, (Carl Zeiss AxioLab A1, CA) and the images were captured with live capture
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module software (Zen, CA) (158). The protransfersome gel was hydrated with 5 mL water and
gently agitated. Then the gel was placed in the well of a concave glass slide, cover slip was placed
on the slide and placed under microscope. Microphotographs of transfersomes formation were
captured at 45X magnification.
5.2.7. In vitro trans-eyelid permeability studies
In vitro trans-eyelid flux was measured using isolated rabbit eyelids as per the methods
established for assessing flux across the skin (147,152). In brief, the rabbit eyelids will be washed
with IPBS (pH 7.4) after removing the hair on the eyelid with epilator and mounted, as an inverted
cup, on the Valia-Chien diffusion cells, such that the conjunctival side of the eyelid face towards
receiver chamber. The donor chamber was then tightly secured so that the eyelid surface will be
exposed to the donor compartment. Accurately weighed optimized PTF or marketed formulation
(Triamcinolone Acetonide cream USP, 0.5 % w/w), equivalent to 1 mg of TA, was applied on the
eyelid surface in the donor chamber. At predetermined time points, 600 µL aliquots was collected
from the receiver cell and replaced with equal volume of fresh medium. The samples were
quantified for the drug content using HPLC-UV method.
Cumulative amount of drug permeated (Mn), steady state flux (J) and trans-eyelid
permeability (Papp), across the rabbit cornea, were estimated in order to study the transport of TA
across rabbit eyelid (147,148). The cumulative amount of TA was calculated as per the equation:
JK

BL M L K

∑OO

K
P BN O P

ML O

P

(2)

Where, n is sampling time point; Vr and VS are the volume in the receiver chamber (mL)
and the volume of the sample collected at the nth time point (mL), respectively and Cr(n) is the
concentration of the drug in the receiver chamber medium at nth time point (µg/mL).
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The rate of TA transported across rabbit eyelid was calculated using the slope of the
cumulative amount of TA transported versus time plot. The steady state flux of TA was determined
using the following equation:
QRSO T

UJ/UV /1

(3)

Where, M is the cumulative amount of drug transported and A is the surface area of the
eyelid (0.636 cm2).
The transcorneal permeability of TA was calculated by the following equation:
WXLYXZ[\R\V] WZ^^
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0aKaL baKbXKVLZV\aK

(4)

5.2.8. Ocular Distribution Studies
Ocular penetration and distribution of TA from optimized PTF and marketed cream
formulations was evaluated on recently sacrificed New Zealand male albino rabbits (within 30 min
after euthanization with excess of pentobarbital). The hair on the right upper eye lid in rabbits were
removed with the aid of epilator and accurately weighed amount of optimized PTF formulation
and marketed TA 0.5 % w/v cream formulation, equivalent to 1 mg of TA, was applied. At the end
of 1h and 2h post application, the eyes were enucleated, cleaned with ice cold IPBS (pH 7.4) and
the ocular tissues were collected. These ocular tissue samples were stored at -80˚C until further
analysis.
5.2.9. Sample preparation
Protein precipitation technique was adopted to extract TA from the ocular tissues. Briefly,
the isolated ocular tissues: conjunctiva, cornea, iris ciliary (IC), retina choroid (RC) and the sclera
were transferred to separate eppendorf tubes. The tissues were dissected into small pieces and 100
µL of 1 µg/mL prednisolone (PR) was added as the internal standard (IS) to each of the tissue
samples. After a while, 1mL ice cold methanol with 0.1% formic acid was added to precipitate the
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proteins. Two hundred microliters of aqueous humor (AH) and 500 µL vitreous humor (VH) tissue
proteins were precipitated using 200 µL and 500 µL respectively, of ice-cold methanol. All
samples were vortexed for about 30 sec and sonicated for 5 min, to extract the drug into the solvent.
Then the samples were centrifuged for 15-30 min at 13,000 rpm, the supernatant was collected and
analyzed for TA content using the UPLC-triple quadrupole (TQ)-MS system.
5.2.10. Bioanalytical method
TA concentration in all the ocular tissues was quantified using Ultra Performance Liquid
Chromatography system coupled with a triple quadrupole mass spectrometer (UPLC-TQ-MS)
(Waters, USA). The peaks of both the drug and the IS (PR)) were quantified with respect to the
specific mass to charge (m/z) values (m/z 435 and 361 for TA and PR, respectively). Two
microliters of the sample were eluted through BEH C18 (100mm×2.1 m, 1.7 µm) Acquity UPLC®
column and separated using an isocratic mobile phase consisting of acetonitrile with 0.1% formic
acid and water with 0.1% formic acid in the ratio of 98:2 respectively. The method showed a limit
of detection (LOD) and quantification (LOQ) of 0.1 ng/mL for TA and IS respectively. All the
instrument functions were operated and managed by Mass Lynx software (version 4.1, Waters,
Milford, MA, USA).
5.2.11. Statistical analysis
A one-way analysis of variance (ANOVA) along with Tukey’s post hoc test (version 5.00;
GraphPad Prism Software, San Diego, CA, USA) was used to analyze the data obtained from the
ocular distribution studies, and the statistically significant difference between the set of
formulations was observed at a ‘p’ value less than 0.05 (p<0.05).
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5.3. Results and Discussion
5.3.1

Physicochemical properties of PTF
PTF formulations were successfully developed changing the ethanol composition, keeping

all other components at same proportions. The physicochemical evaluation parameters are
enumerated in Table 5.1. The drug loading in all the PTF formulations (~ 1% w/w) were ~ 2 folds
higher, compared to the topical triamcinolone USP marketed cream dosage form (0.5 % w/w),
with ~92- 96 % assay (Table 5.1). The content uniformity of the PTF 1 formulation was 80.2 ±
11.5, which was lower than that seen in PTF 2 and PTF 3 formulations. This suggests poor
distribution of TA in the lipid matrix at this proportion of ethanol. The particle size of the PTF
formulations (184.5 – 336.4 nm) decreased to some extent as the ethanol composition increased
but, it increased again upon further increase in the ethanol proportion (Table 5.1). In contrast, the
% EE in the PTF formulations increased upon increase in the amount of ethanol to an extent but it
decreased again upon further increase in the ethanol amount in the formulation (Table 5.1). It has
been reported that in the vesicular systems, ethanol helps in i) lowering the transition temperature
of the lipids, and thereby, allows the lipophilic drug partitioning into the phospholipid bilayers; ii)
attaining the gel phase due to regular arrangement of bilayer components, unlike liquid crystalline
phase where irregular arrangement of PL and CH is seen; and, iii) permeability of the bilayer
membrane (158, 165-167). Thus, at lower ethanol proportion the TA partitioning into lipid
components was less which resulted in larger transfersomes with less drug entrapment. While at
higher concentration of ethanol, the %EE dropped due to increased permeability of the bilayer
membrane. Hence, PTF 2 formulation, which formed 184.5 nm size transfersomes with ~90% EE,
was optimized and taken for further studies (Table 5.1).
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5.3.2

Polarized Microscopy

Figure 5.1: Optical polarized microscopic images of (A) pure TA B) PTF 2.

Polarized microscopic images of pure TA and PTF 2 formulations are presented in Figure
5.1. The optical birefringence of pure TA showed interference colors (Fig 5.1A). The polarized
optical microscopic images of PTF 2 formulation revealed the absence of crystalline drug in the
gel formulation, confirming the solubility of drug in lipid phase (Fig. 5.1B).
5.3.3

Formation of Transfersomes from PTF

Figure 5.2: Photomicrographs showing the formation of transfersomes under optical microscope: (A) gel
surface immediately after hydration, B) Tubular structure formation, C) Transformation of tubular projection
to vesicular form and D) Multilamellar transfersomes.
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The formation of transfersomes from PTG formulation are illustrated in Figure 5.2. The
optical microscopic studies demonstrated projection of globular structures on the surface of gel
matrix (Fig. 5.2A), initially upon hydration of PTF 2, and they transformed into tubular structure
(Fig. 5.2B and Fig. 5.2C) and finally, formed as multilamellar transfersomes (Fig. 5.2D). These
findings were consistent with the earlier reports which demonstrated the formation of liposomes
from proliposomes gel formulation (158).
5.3.4

In vitro trans-eyelid permeability study

Trans-eyelid permeability parameters of TA from marketed and PTF 2 formulations are given in
Table 5.2. The results from in vitro trans-eyelid permeation studies suggested a ~2-fold
improvement in TA flux and permeability across the eyelid with the PTF 2 (p<0.05) formulation
compared to marketed dosage form (Table 5.2). This demonstrates efficient partitioning of the
lipid vesicles into the intercellular lipid layers in the eyelid - thus, increasing the permeation (150,
152-1754). Reports in the literature demonstrated immediate formation of vesicles from the provesicular gel formulation and increased vesicle-skin interaction (152-154). The phospholipid in

Table 5.2: In vitro trans-eyelid permeability parameters of TA from optimized PTF and marketed
formulations (mean± SD; n=3)

-

Formulation

Flux (µg/h/cm2)

Papp x 10 5 (cm2/h)

Triamcinolone acetonide
USP, 0.5% w/w

0.31 ± 0.16

6.3 ± 3.2

PTF 2

0.69 ± 0.28*

13.8 ± 5.6*

PTF 2 and Papp indicates the optimized protransfersome gel formulation and apparent permeability,
respectively.

-

*- represents the level of significance at p<0.05 between PTF 2 and triamcinolone acetonide marketed
formulation.

the vesicle structure allows immediate partitioning of this flexible vesicle, transfersomes, into the
lipid layers of the eyelid through the intercellular passages (17-19). Moreover, the destabilization
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of skin layers by Span 60 and TPGS results in improved permeation of TA across the eyelid (155,
157-159,161).
5.3.5

Ocular Distribution Studies
TA levels in different ocular tissues of the rabbits (carcass) treated with PTF 2 and

marketed formulation was delineated in Table 5.3. ~2-13 fold higher TA levels were seen in the
conjunctiva, cornea and sclera of the rabbits receiving the PTF 2, in contrast to the marketed
Table 5.3: The levels of triamcinolone acetonide from PTF 2 and marketed formulation in the rabbit ocular
tissues, at 1h and 2h post eyelid application (mean ± SEM; n=3).

Ocular tissues

Formulations

PTF 2

Marketed

Time (h)

1

2

1

2

Conjunctiva (µg/g)

4.78 ± 1.04 *

8.5 ± 2.79 *

2.3 ± 1.19

2.38 ± 0.5

Cornea(µg/g)

4.24 ± 0.96 *

13.04 ± 0.56 *

0.32 ± 0.32

1.76 ± 0.96

IC (µg/g)

0.68 ± 0.079*

0.88 ± 0.061*

0.20 ± 0.056

0.47 ± 0.019

AH (ng/mL)

54.03 ± 7.43 *

125.32 ± 27.91 *

21.19 ± 12.37

40.54 ± 1.19

Sclera (µg/g)

11.07 ± 5 *

11.45 ± 1.8 *

0.45 ± 0.15

1.2 ± 0.25

RC (µg/g)

1.07 ± 0.003*

1.79 ± 0.4 *

0.21 ± 0.14

0.52 ± 0.06

VH (ng/mL)

6.25 ± 1.37 *

43.66 ± 17.84 *

1.20 ± 0.40

4.5 ± 0.71

IC-Iris-ciliary body; AH-aqueous humor; VH-vitreous humor; RC-retina-choroid
*-indicates significantly different with respect to the marketed formulation, at respective time point (p<0.01)

formulation (p<0.05) (Table 5.3). The TA levels seen in these ocular tissues of the rabbits treated,
with PTF 2, were upto 2-fold higher at the 2h time point, compared to 1h (Table 5.3).
This suggests continuous absorption of TA from PTF, through the eyelid, into conjunctiva
and other exterior ocular tissues, which will thus allow a sustained ocular delivery platform.
Furthermore, at any given time point, the TA levels in the rabbits receiving the protransferosome
gel formulation was significantly better than those treated with marketed formulations (p<0.05)
(Table 5.3). The results demonstrated greater permeability characteristics, of protransfersome gel
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system, through the eyelid, thus presented drug to the deeper ocular tissues (147,150,152). The
only in vivo trans-eyelid delivery investigation reported dexamethasone levels in the anterior
segment ocular tissues following the application of a poloxamer gel formulation on the eyelid of
conscious rabbits (150). The permeability of TA and dexamethasone through ocular tissues has
been reported to be largely similar due to the similar physicochemical behavior (168,169). In view
of this, the levels of TA seen in the conjunctiva, cornea and AH with the protransfersome gel
formulation were comparable with those obtained with dexamethasone from the poloxamer based
gel formulation at the 2h time point. TA levels were also noticed in back-of-the eye tissues, the
vitreous humor and retina-choroid. Furthermore, the levels of TA in ocular tissues, especially in
AH and VH were significantly higher than the minimum therapeutic concentrations of TA - 1.7
and 6.5 ng/mL, respectively (170-172).
5.4. Conclusion
TA protransfersome gel formulations were successfully prepared with at least a two-fold
higher drug load, compared to the marketed topical dosage form, which allows higher, localized,
concentration gradients. Microscopic studies confirmed complete drug dissolution in the lipid
phase and rapid formation of transfersomes on hydration. Significantly higher trans-eyelid TA
permeation with the protransfersome gel formulation – demonstrated their potential in enhancing
drug delivery to the ocular surface and deeper tissues via the eyelid. Experiments in rabbit
carcasses confirmed that TA efficiently penetrated into the eyelid and formed a depot leading to
improved concentration-time profiles in all ocular tissues tested. The overall results suggest that
trans-eyelid protransferosome gel formulations can provide a platform for the sustained delivery
of therapeutic agents to both the surface of the eye as well as the anterior and posterior segment
ocular tissues.
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